

REVIEW

View Article Online
View Journal | View Issue



Cite this: *J. Mater. Chem. B*, 2023, 11, 7834

Tuning foreign body response with tailor-engineered nanoscale surface modifications: fundamentals to clinical applications

Tara Chand Yadav ^{ab} and Akash Bachhuka ^{*b}

Biomaterials are omnipresent in today's healthcare services and are employed in various applications, including implants, sensors, healthcare accessories, and drug delivery systems. Unfavorable host immunological responses frequently jeopardize the efficacy of biomaterials. As a result, surface modification has received much attention in controlling inflammatory responses since it helps camouflage the biomaterial from the host immune system, influencing the foreign body response (FBR) from protein adsorption to fibrous capsule formation. Surfaces with controlled nanotopography and chemistry, among other surface modification methodologies, have effectively altered the immune response to biomaterials. However, the field is still in its early stages, with only a few studies showing a synergistic effect of surface chemistry and nanotopography on inflammatory and wound healing pathways. Therefore, this review will concentrate on the individual and synergistic effects of surface chemistry and nanotopography on FBR modulation and the molecular processes known to modulate these responses. This review will also provide insights into crucial research gaps and advancements in various tactics for modulating FBR, opening new paths for future research. This will further aid in improving our understanding of the immune response to biomaterials, developing advanced surface modification techniques, designing immunomodulatory biomaterials, and translating discoveries into clinical applications.

Received 7th May 2023,
Accepted 14th July 2023

DOI: 10.1039/d3tb01040f

rsc.li/materials-b

Introduction

Biomaterials play a vital role in the current medical system, with applications ranging from implantable devices (orthopedics and cardiovascular) to controlled drug delivery (vaccines and genes), diagnostics, and imaging (cancer treatment).¹ The implantation of a biomaterial inside the human body triggers an elaborate network of events known as the foreign body reaction (FBR), which includes plasma-material interaction, acute and chronic inflammation, matrix formation, tissue granulation, and fibrosis.² The ability of a biomaterial to function may be jeopardized by the innate inflammatory reactions elicited by an FBR. The earliest responders to the implanted biomaterial are innate immune cells such as neutrophils, dendritic cells, macrophages, natural killer cells, T-cells, and B-cells. These cells identify the biomaterial as alien and trigger an immune response by producing cytokines and

chemokines that recruit additional immune cells to the implant site. These cytokines and chemokines also activate the complement system, a protein set that works together to remove foreign invaders. When the complement system is engaged, it might create inflammation, stimulate phagocytosis, and attract extra immune cells to the implant site. The adaptive immune response begins when T-cells and B-cells recognize specific antigens on the implanted biomaterial. Antigens are molecules the immune system recognizes as foreign and causes an immunological response. T-cells help to coordinate the immune response by releasing cytokines that stimulate other immune cells, whereas B-cells create antibodies that bind to specific antigens. The adaptive immune response to the implanted biomaterial can be beneficial and deleterious. Although the immune system's reaction is necessary for tissue regeneration at the implantation site, prolonged cytokine stimulation and forming reactive oxygen species radicals and enzymes can lead to implant degradation.³ Thus, modulating the host immune system's reaction is of utmost importance when assessing outcomes and the long-term efficacy of the implanted biomaterial.

Recent breakthroughs in biomaterial research have focused on customizing the shape and properties of the implant's

^a Department of Bioinformatics, Faculty of Engineering & Technology, Marwadi University, Gujarat, 360003, India

^b Department of Electronics, Electric, and Automatic Engineering, Rovira I Virgili University (URV), Tarragona, 43003, Spain. E-mail: akash.bachhuka@urv.cat; Tel: +(34) 643201339



nanoscale surface to influence the host immune system response and increase the implanted biomaterial's long-term efficacy.⁴ It has been established that the biomaterial's surface nanotopography modulates protein adhesion, hence influencing the binding and activation of innate immune effector cells.⁵ It is feasible to regulate the immune response and impact the behavior of immune cells such as macrophages, which play a critical part in the foreign body reaction, by precisely manipulating the nanoscale characteristics of the implant surface. The implant surface's nanoscale pattern can be customized to promote or inhibit various macrophage phenotypes, such as the pro-inflammatory M1 or anti-inflammatory M2 phenotypes.⁶ Surface features that resemble the natural extracellular matrix or give cues for immune cell interactions can be created using nanopatterning, nanogrooving, or nanotexturing techniques.⁴ These designed surfaces can control the release of immunomodulatory signals, modulate cytokine production, and steer macrophage polarization toward a particular phenotype. Furthermore, the nanoscale surface features of the biomaterial can be changed to improve biocompatibility and integration with the surrounding tissues. Surface changes, such as adding bioactive compounds, growth factors, or immunomodulatory drugs, can stimulate tissue regeneration while decreasing the foreign body response.⁷ Furthermore, antimicrobial chemicals or coatings applied to the nanoscale surface can help prevent infections and improve the long-term functioning of the implanted biomaterial.⁸

Understanding the interplay between macrophages and biochemical cues in a biomaterial-based foreign body response is critical in designing, fabricating, and developing immuno-

modulatory biomaterials. Modulating macrophages and FBR via various surface features (chemistry and nanotopography) of the implanted biomaterial have attracted a lot of attention recently.^{9–11} The surface nanotopography of the biomaterial influences protein adhesion, impacting the binding and activation of innate immune effector cells.¹²

This review paper provides a comprehensive summary of recent achievements and improvements in biomaterial research, particularly emphasizing the synergistic effects of the nanoscale surface features of implants in influencing the host immune system response. It highlights the need to modify the nanoscale shape and characteristics of implant surfaces to control immune cell behavior during the foreign body reaction. Its focus on nanoscale-level customization and its implications for biocompatibility, tissue integration, and patient outcomes make it a valuable resource for researchers, clinicians, and industry professionals interested in designing and developing immunomodulatory biomaterial implants.

1. Foreign body response (FBR) to biomaterial implants

Internalization of an exogenous graft/biomaterial (medical implant devices) causes an immune response (FBR), which includes a series of actions involving several cell types and sophisticated biochemical signals involved in critical regulatory mechanisms (Fig. 1).¹³ FBR-mediated inflammation is initiated with the adsorption of nonspecific serum proteins onto the biomaterial's surface.¹⁴ The major serum proteins known to



Tara Chand Yadav

Dr. Tara Chand Yadav is a postdoctoral scholar at Universitat Rovira i Virgili. He completed his PhD at the Department of Biosciences & Bioengineering, Indian Institute of Technology Roorkee, in 2021. His thesis involves synthesizing, characterizing, and formulating colloidal drug delivery systems using the nanomedicine approach for biomedical applications. To date, he has (co)authored 10 invited book chapters and 15 SCI

journal papers. His current research focuses on improving the drug-release kinetics of antibiotics to enhance antimicrobial efficacy via sustained-release formulation.



Akash Bachhuka

Dr. Bachhuka was awarded a PhD in Material science and Engineering from the University of South Australia (UniSA) in 2016. During this time, his study focused on understanding the mechanisms underpinning cell-surface interactions. Following his PhD, he worked as a post-doctoral researcher at the University of Adelaide's ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), where he developed microstructured optical fiber-based

chemical sensors and biosensors. As an emerging research leader, he has published more than 45 research papers and book chapters. In 2020, he was awarded the prestigious "Juan de la Cierva incorporation" fellowship and was ranked 6th in Materials Science and Engineering in Spain. More recently, in 2022, he was awarded the Marie Curie Cofund (BP21) individual fellowship and was ranked among the Top 10 researchers in Engineering, Technology, and Architecture in Catalunya, Spain. His multidisciplinary research focuses on nanoengineered surfaces for a variety of applications, including medical implants, biosensors, and chemical sensors.





Fig. 1 Host response following implantation. The graphic depicts the sequence of events in the host reaction after implantation, highlighting crucial stages in the foreign body response. (1) Implant insertion leads to the adsorption and desorption of serum proteins from the adjacent vasculature onto the implant surface *via* the Vroman effect. (2) This procedure promotes the infiltration and adhesion of different cells, such as macrophages, monocytes, and blood platelets. (3) The attracted cells release cytokines and chemokines, resulting in the formation of a chemotactic gradient that attracts tissue repair cells, such as fibroblasts, to the inflammatory site. (4) Fibroblasts play a crucial role by depositing a collagen matrix, primarily composed of Collagen I, II, and III. This matrix encapsulates the biomaterial, forming a fibrous tissue layer that promotes angiogenesis.

readily adsorb onto the biomaterial's surface are fibrinogen, fibronectin, albumin, vitronectin, immunoglobulins, and complementary proteins.^{15–17} The amount and type of these adsorbed proteins influence immune cell adhesion *via* multiple receptors, directing their differentiation toward the inflammatory or anti-inflammatory pathway.⁵ Moreover, the cascade of events underlying FBR involves the activation of acute and chronic inflammation due to the interaction of blood with biomaterials and the creation of a provisional matrix.¹⁸ Early signs of acute inflammation that occur after biomaterial implantation often disappear within a week and are accompanied by a substantial inrush of neutrophils within hours of implantation. The release of cytokines soon after neutrophil extravasation attracts monocytes, which are helped further

by neutrophil phagocytosis by macrophages gathered near the implant site.¹⁸ Neutrophils typically have a short lifespan, whereas monocytes can survive for extended periods by differentiating into macrophages. Furthermore, neutrophils and monocytes drawn to the implant release a variety of chemokines and pro-inflammatory cytokines that promote immune cell movement and the generation of reactive oxygen species (ROS), significantly impacting monocyte viability and macrophages.¹⁹ Chronic inflammation begins four to seven days after implant insertion, as evidenced by a proliferation of lymphocytes and macrophages surrounding the implant site. T-cells are attracted throughout the chronic inflammatory phase and have been demonstrated to significantly impact macrophage activation *via* a subsequent cycle. After dendritic cell stimulation, T-cells can be polarized towards



TH1 or TH2 development.²⁰ Activated T-cells can generate additional cytokines, implicitly polarizing macrophages towards a pro-inflammatory or preparative phenotype. In a pro-inflammatory state, macrophages release high levels of cytokines and ROS to break down or disintegrate the implanted biomaterial.²¹ The immune system's heightened response stimulates adherent macrophage fusion, producing foreign body giant cells (FBGCs). This causes the formation of a biological wall that engulfs the implant within a fibrous tissue layer of collagen, other extracellular matrix proteins, and tissue-repair cells designed to degrade the implant. However, the fibrotic capsule can impact the implanted biomaterial in good and unfavorable ways. On the one hand, it can shield host tissue from the implant, prevent infection, and lower the likelihood of implant failure. On the other hand, it can restrict the passage of nutrients and oxygen to the implant and delay its integration with the host tissue.²² Hence, minimizing the subsequent phases of the pro-inflammatory innate response cascade in the context of implant effectiveness is of the utmost importance. Table 1 depicts the various stages of foreign body reaction and their accompanied timings, allowing for an understanding of the temporal course of the host's response to biomaterial implants.

2. Acute inflammation

Acute inflammation is an important early FBR event arising from implanted biomaterials. The inflammatory reaction is triggered by the degranulation of neutrophils and mast cells, releasing histamines. Neutrophils degrade implants primarily by producing reactive oxygen species (ROS), proteolytic enzymes, and neutrophil extracellular matrix (NETs).²⁵ These NETs are made up of a network of granular proteins, neutrophil elastase, chromatin DNA, and histones with bactericidal activity and "sticky" properties that allow pathogens to be captured and infection spread to be prevented. The role of NETs in implantable biomaterial-induced inflammation, if any, remains unknown.

Concurrently, circulating monocytes are drawn to the implant site and divided into classical or M1 macrophages on the implant's surface. These activated M1 macrophages secrete a variety of pro-inflammatory cytokines such as tumor necrosis

factor (TNF) α , interleukins (IL) 1 β , and IL6 as well as reactive oxygen species (ROS) and degradative enzymes, like neutrophils, to destroy the implant.^{26,27} When macrophages cannot destroy or phagocytose these implants, they enter a state of frustrated phagocytosis, resulting in an enormous release of pro-inflammatory cytokines. Adherent macrophages gradually transform into an alternatively activated or "M2" phenotype with lesser degradative capacities, the release of anti-inflammatory cytokines, including IL-10, and tissue remodeling activity similar to wound healing processes. The transition from M1 to M2 phenotype and the mechanisms of frustrated phagocytosis induce macrophages to fuse on the biomaterial surface to form a foreign body giant cell (FBGC), which improves their phagocytic activity.²⁸

3. Chronic inflammation

Chronic inflammation is caused by the fusing of macrophages to form FBGCs, which is aided by mast cells, basophils, and T Helper (Th) cells, through the release of IL-4 and IL-13.²⁹ To degrade implants, these FBGCs release pro-inflammatory cytokines such as IL-6, IL-1 β , TNF α , RANTES (regulated upon activation of normal T cell produced and presumably secreted), MCP-1 (monocyte chemotactic protein-1), and IL-8.^{30,31} Pro-inflammatory cytokine expression declines over time. In contrast, anti-inflammatory cytokines such as IL-10, transforming growth factor (TGF), and IL-1 receptor become antagonistic, marking the start of the tissue remodeling process. TGF and platelet-derived growth factors (PDGF) are produced by FBGCs, which attract fibroblasts and endothelial cells to the implant site.³² Activated fibroblasts initially secrete collagen III fibers smaller in diameter than collagen I, which are eventually replaced by more organized collagen I, providing the healing structure with additional tensile strength.^{33–35} Collagen production benefits wound healing and tissue remodeling, but excessive secretion causes fibrosis. In combination with FBGCs, excess collagen produces a fibrous capsule around the implant, isolating it from the rest of the body. Toxins, oxides, and nitrides secreted by giant fibrous cells in the fibrous capsule by macrophages and leukocytes can cause implant rejection or failure. This sequence of events emphasizes the relevance of macrophages, neutrophils,

Table 1 Stages of foreign body response (FBR) and subsequent timeline^{5,23,24}

Foreign body response phases	Onset of events	Time-period
Implanted biomaterial	The surgical incision to implant a biomaterial or biomedical device inside the body drives tissue or organ injury, initiating an inflammatory response.	$t = 0$
Adsorbed protein	The proteins in the blood will adhere to the biomaterial's surface, activating the blood coagulation and complement systems as well as platelets.	$t > 1$ s
Recruiting inflammatory cells	Inflammatory cells, primarily polymorphonuclear leukocytes (PMNs), are drawn to the implantation zone. Activated PMNs release chemokines as chemical attractants for monocytes, macrophages, embryonic dendritic cells, and lymphocytes.	$t = 60$ min
Cell adhesion to the biomaterial	Monocytes develop into macrophages, which cling to the outermost layer of the biomaterial and produce reactive species to break down and phagocytose it. Macrophages merge and create gigantic foreign body cells (FBGCs) in more extensive materials.	$t = 1$ –15 days
Development of fibrous capsule	Transforming growth factor (TGF- β) and platelet-derived growth factor (PDGF) are factors released by macrophages and FBGCs that draw in and stimulate fibroblasts and endothelial cells, respectively. Active fibroblasts will produce collagen, resulting in the development of a fibrous capsule and leading to the encapsulation of biomaterial.	$t = 3$ –4 weeks



fibroblasts, and collagens in the foreign body cascade underlying implantation.³⁶

4. Mechanisms underlying the foreign body response (FBR)

FBR is characterized by an inflammatory reaction involving macrophages at the implant site. On the other hand, excessive activation of macrophages might result in a persistent inflammatory response, eventually culminating in the production of a protective collagen-rich sheath around the implant. This procedure will continue until the implant is removed from the patient's body.³⁷ However, the processes that drive the FBR are largely unclear, and effective techniques to prevent or minimize its deleterious impact without interfering with tissue regeneration are required. To that goal, researchers have investigated different ways, such as local delivery of anti-inflammatory or antifibrotic medicines at the interface between the device and surrounding tissue, as well as optimizing the physical features of the implant to reduce FBR. Nonetheless, these treatments have had limited effectiveness, and local administration of broad-spectrum anti-inflammatory drugs such as dexamethasone has been offered as a viable remedy.³⁸

Despite ongoing research efforts, our understanding of how surface modifications such as surface nanotopography and chemistry influence cellular responses underlying FBR needs to be completed.⁴ Despite this, some underlying mechanisms contributing to the FBR have been identified. The following are a few of the known mechanisms.

4.1. Cell-surface interaction *via* integrins

The initial adsorption of non-specific proteins onto the surface of implants sets off a chain of events that can impact post-operative inflammation and wound healing. Several proteins that bind to the surface of implanted materials have been identified, and the surface features of the implant determine the degree to which these proteins adhere. The composition and content of the adsorbed proteins can influence immune cell recognition and activation, thus regulating the foreign body response (FBR).¹² *In vitro* studies have shown that proteins are adsorbed onto biomaterial surfaces based on surface-free energy, promoting cell adhesion to the surface. Integrin surface receptors such as fibronectin, laminin, tenascin, and thrombospondin bind primarily to surface-adsorbed proteins such as fibrinogen, vitronectin, and fibronectin *via* RGD (Arginine–Glycine–Aspartic acid) peptide signaling pathways.³⁹

Within the extracellular matrix (ECM), integrin-mediated cell-receptor ligation occurs, resulting in integrin clustering towards the cell membrane (Fig. 2). After adhering to integrins, ECM interacts with actin filaments *via* adaptor proteins like talin and vinculin. This interaction between the ECM and integrins allows the cell to analyze the physical features of the ECM and change its shape as needed.²³ Fibrinogen, a surface-attaching protein, was found to trigger inflammation when it binds to the integrin Mac-1 receptor.⁴⁰ Macrophages bind to the tri-peptide



Fig. 2 Cell–surface interaction and extracellular matrix (ECM) engagement. The graphic depicts the process of integrin-mediated cell–surface contact and subsequent engagement of the extracellular matrix (ECM) to influence cellular activity. This interaction causes integrin clustering at the cell membrane by causing cell-receptor ligation within the ECM. The ECM interacts with actin filaments *via* adaptor proteins such as talin and vinculin after attachment. This interaction allows the cell to explore the physical features of the ECM, allowing the cell to gather information about its surrounding microenvironment. The cell undergoes dynamic shape changes based on the information gathered, changing its morphology and cytoskeletal organization.

sequence Arg–Gly–ASP (RGD) through α M β 2 integrin, the Mac-1 receptor. The integrin Mac-1 receptor and RGD-binding integrins also influenced the *in vivo* FBR to subcutaneously implanted polyethylene terephthalate. A fragile foreign body capsule emerged in the absence of integrin Mac-1 (about 30% thinner) or by a monitored release of an inhibiting peptide to prevent binding of the RGD-binding integrins (roughly 45% thinner). These findings show that the integrins Mac-1 and RGD-binding integrins are important in decreasing macrophage inflammatory responses to microscopic and bulk biomaterials, implying that they could be promising therapeutic targets.⁴¹

Surface modifications, such as surface chemistry, can immediately impact how macrophages interact with the implant. The precise mechanisms by which integrins regulate macrophage motility, phagocytosis, and activation remain unknown.⁴² However, Cha *et al.* demonstrated that promoting integrin-mediated connections between the collagen-derived matrix and human monocytic THP-1 cells can modulate macrophage polarity near the implant site. The implant environment appears to influence macrophage polarization by modulating the influence of effective M2 or M1 phenotypic activators such as IL-4 and lipopolysaccharide (LPS). Moreover, integrin α 2 β 1 plays an important role, primarily because reducing its activity reduces M2 macrophage production.⁴³ Cell adhesion to the ECM is critical for modulating cell proliferation and differentiation on biomaterial surfaces. Cell migration is enabled by the formation of thin sheets of lamellipodia and filopodia on biomaterials. Filopodia detects adsorbed protein ligands and directs cells toward the targeted ligand interaction site.⁴⁴ Understanding the complicated



interactions between implanted material, adsorbed proteins, and immune cells is critical for designing effective ways to prevent FBR and promote tissue regeneration in implanted devices.

4.2. Role of inflammasome in the FBR-surface cascade

Inflammasome is an intracellular multi-complex protein in cells that secrete pro-inflammatory cytokines such as IL-1 β and IL-18 (Fig. 3). Several types of inflammasomes have been identified, including nucleotide-binding oligomerization domain receptors (NOD)-like receptor (NLR-NLRP1, NLRP3, NLRP6, NLRP12), IL-1 β -converting enzyme protease-activating factor (Ipaf), and absent in melanoma (Aim2).⁴⁵ Several studies have shown that surface-independent cytosolic receptors, such as the Nod-like receptor cryopyrin 3 (NLRP3), can activate and promote the FBR. The NLRP3 inflammasome is a cytosolic molecular scaffold that is especially important to biomaterials during the acute inflammatory phase of the FBR because it releases pro-inflammatory cytokines such as IL-1 and IL-18. Activation of Pannexin -1 protein *via* adenosine triphosphate (ATP) interaction with P2X purinoceptor 7 (P2X7) receptors, cytosolic crystalline uric acid and cholesterol, and foreign particles such as alum and asbestos can all activate the inflammasome.²³ It can also be induced by the physical interaction of innate immune cell membranes with biomaterial implants. Toll-like receptor (TLR) stimulation also typically initiates NLRP3 inflammasome activation, which activates NF κ B and increases NLRP3 expression, enhancing intracellular sensing. Nanoparticulate carbon, polystyrene, amorphous silica, TiO₂, and silver have all recently been discovered to

activate the inflammasome and build an FBR. Inflammasomes recruit and activate apoptosis-associated speck-like proteins containing a CARD (ASC) and Caspase-1, which cleave pro-IL-1 and pro-IL-18 to generate IL-1 and IL-18, resulting in inflammation. Although the NLRP3 inflammasome is a powerful driver of an FBR's acute phase, it does not appear to contribute to its complete development, which depends on the ASC-mediated inflammasome.⁴⁶ As a result, other ASC-dependent NLRs must also be involved in FBR progression.

James Anderson's contributions to this field have been substantial, providing a pathology-based perspective on FBR in biomaterials (Table 2).^{23,24,47} Franz *et al.*⁴⁸ stressed the significance of designing biomaterials that can control immune responses. In contrast, Christo *et al.*⁵ focused on the role of inflammasomes in the immune system's response to biomaterials. They created modeled substrates with precise nanotopography and surface chemistry. They discovered that the inflammasome elements ASC, NLRP3, and AIM2 were critical in modulating macrophage activation and adhesion in response to surface nanotopography and chemistry.⁴⁹ Turley *et al.* developed different chitosan polymer mixes with varying degrees of deacetylation and discovered that a high degree of deacetylation increased NLRP3 inflammasome stimulation.⁵⁰ Using biomaterials too big to be phagocytosed, researchers found that the NLRP3 inflammasome is involved in phagocytosis-independent inflammatory reactions.⁵¹ Court *et al.* discovered that collagen 3D scaffolds induced the development of the NLRP3 inflammasome, which resulted in increased IL-1 production in human macrophages.⁵² Vasconcelos *et al.* reported that




Fig. 3 A simplified schematic of inflammasome activation and progression. When sensor proteins recognize stimulatory ligands, the inflammasome is activated. The NLRP3 sensor is activated *via* stimulation of a Toll-Like Receptor (TLR). Through their PYD, NLRP3 sensors recruit ASC, allowing interactions with procaspase-1 *via* CARD–CARD interactions. This complex creates a wheel-like shape that aids procaspase-1 cleavage into caspase 1. Caspase 1 then converts pro-IL-1 and pro-IL-18 into their active counterparts, IL-1 and IL-18, which are ultimately released to stimulate inflammatory responses.



Table 2 Biomaterial-mediated activation of the inflammasome pathway

Biomaterials	Response	Ref.
Carbon nanoparticles	Activation of caspase-1 increased IL-1 β production	Reisetter <i>et al.</i> ⁵⁴
Amino-functionalized polystyrene nanoparticles	Assembly of the NLRP3 inflammasome increased IL-1 β production	Lunov <i>et al.</i> ⁵⁵
Carboxyl-functionalized or non-functionalized polystyrene nanoparticles	No effect on the inflammasome pathways was observed	
Silica nanoparticles	Increased levels of IL-1 β through inflammasome pathway activation	Gómes <i>et al.</i> ⁵⁶
Titanium dioxide nanoparticles	Increased gene expression of NLRP3, caspase-1 and IL-1 β	Oshaghi <i>et al.</i> ⁵⁷
Chitosan-aluminum nanoparticles	Activation of the NLRP3 inflammasome increased IL-1 β production	Lebre <i>et al.</i> ⁵⁸
Micro-scale based biomaterials		
Cobalt–Chromium–Molybdenum alloy microparticles	Irregular and larger microparticles induced higher levels of IL-1 β through inflammasome pathway activation	Caicedo <i>et al.</i> ⁵⁹
Hydroxyapatite microparticles	Smaller and needle-shaped microparticles lead to activation of the NLRP3 inflammasome, and increased IL-1 β production	Lebre <i>et al.</i> ⁶⁰
Microspheres of poly(methyl methacrylate)	Activation of caspase-1 further secretion of IL-1 β	Malik <i>et al.</i> ⁵¹
Large-scale based biomaterials		
Collagen 3D scaffolds	Induced assembly of the NLRP3 inflammasome increased IL-1 β secretion	Court <i>et al.</i> ⁵²
3D chitosan scaffolds	Impaired NLRP3 inflammasome assembly	Vasconcelos <i>et al.</i> ⁵³

3D chitosan scaffolds inhibited the formation of the NLRP3 inflammasome in macrophages, contradicting a prior study that demonstrated chitosan as an inducer of the NLRP3 inflammasome in nanoscale chitosan derivatives.⁵³ Despite its importance, there still needs to be an explanation for how different biomaterials activate the inflammasome pathway. More in-depth investigations into the involvement of different inflammasome components are required to thoroughly explain the system's stimulation in the inflammatory response to biomaterials. Nonetheless, modulating inflammasome activity is an essential method for establishing successful routes for biomaterial integration, which is a critical barrier in regenerative therapeutic therapy.

4.3. Protein adsorption and unfolding

Protein adsorption and unfolding on biomaterial surfaces can influence immune cell activity significantly. Many proteins undergo structural modifications upon adsorption onto biomaterial surfaces, revealing hidden epitopes or antigenic determinants for immune cell receptors. These modifications may affect an immune cell's ability to recognize and interact with adsorbed proteins. Scavenger receptors, for example, are found on immune cells called macrophages and connect to exposed peptide sequences formed by protein unfolding on the surface. The binding of these receptors to the adsorbed proteins can activate immune cells and produce cytokines, resulting in an inflammatory reaction.^{61,62}

The roughness of biomaterial surfaces is essential in determining protein adsorption, unfolding, and the subsequent immune response. Recent research has emphasized the significance of protein unfolding in revealing hidden epitopes for immune cell receptors. For example, Visalakshan *et al.* studied the impact of protein unfolding in regulating fibrinogen-immune cell interactions. The researchers reported that fibrinogen adsorption on a biomaterial surface caused conformational changes that exposed hidden epitopes, resulting in greater macrophage adherence and activation.⁶³ In another study, Dabare *et al.* explored the effects of surface nanotopography on albumin adsorption and unfolding behavior, as well as related immunological reactions. They observed that the percentage of immobilized albumin increased when the

surface area increased due to increasing nanotopography dimensions. The protein experienced structural changes and lost alpha-helical structures. THP-1 immune cells interacted with surface-adsorbed albumin *via* scavenger receptors that bind to exposed peptide sequences produced by albumin unfolding on the surface. Depending on the peptide sequence revealed, the immune response might be pro-inflammatory or anti-inflammatory. This investigation's findings could lead to biomedical implants' development with tailored surface nanotopography and albumin pre-adsorption to improve biomedical implants' biocompatibility and accelerate wound healing.¹⁴ According to another study, albumin unfolds and exposes its cryptic epitopes in domains I and II to connect with the macrophage scavenger receptor-A1.⁶⁴ Several studies have also found that temperature, pH, buffer concentration or composition, and nanoparticle concentration all influence albumin conformational change. With the rising temperature, native albumin transforms from reversible to irreversible in thermodynamic equilibrium. Albumin responds to pH variations by unfolding; at acidic pH, for example, domain III mostly experiences structural changes, whereas domain II becomes a molten molecule. The albumin molecule is isomerized at basic pH in domains I and II. Albumin adsorption and conformational stability have been altered by varying ionic strengths. The effect of nanotopography on albumin structural alteration and subsequent immune responses is uncommon, and more research is needed.⁶⁵ A schematic representation of the protein adsorption and unfolding on nanotopography-modified surfaces has been presented in Fig. 4. The graphic depicts the nanoparticle size dependent adsorption and unfolding of proteins (albumin, fibrinogen and IgG). Understanding the relationship between protein adsorption, unfolding, and subsequent immune cell responses is necessary when designing biomaterials to promote tissue repair and regeneration.

5. Effect of a biomaterial's physicochemical properties on the FBR

A biomaterial's physicochemical properties, such as chemistry, charge, size, shape, composition, and roughness, play a vital





Fig. 4 Modulation of protein adsorption and unfolding on nanopotography-modified surfaces. The graphic depicts the effect of nanopotography feature size on serum protein adsorption onto nanopotography-modified surfaces. The feature size of nanoparticles influences protein adsorption, resulting in differential unfolding of proteins such as albumin, IgG, and fibrinogen. The size-dependent unfolding reveals hidden receptors on these proteins, which are important in guiding cell–surface interactions. Understanding the relationship between the size of nanopotography features and protein adsorption and unfolding is critical for understanding the mechanisms underlying cellular responses to nanomaterials and creating surfaces that can modify cell activity depending on specific protein interactions.

role in modulating the events underlying the foreign body response (FBR).^{66–68} Understanding the link between biomaterial physicochemical attributes and the FBR is crucial for creating biomaterials that evoke a minimal immune response and enhance tissue regeneration. This review will critically review the individual and synergistic effects of these surface qualities on FBR in detail.

5.1. Role of surface chemistry in regulating the FBR cascade

5.1.1. Surface chemistry's influence on protein and immune cell binding. Researchers explored the effect of surface chemistry on the binding of proteins and immune cells to the surface of a biomaterial. They investigated various strategies for modifying surface chemistry, such as chemical grafting, self-assembled monolayers, and plasma polymerization. Each approach has been examined to see how it affects the attached protein's amount, content, and conformational changes.^{69,70} Studies have shown that proteins bind to hydrophobic surfaces more strongly than hydrophilic surfaces. Still, insufficient translation of these discoveries into *in vivo* outcomes has encouraged re-examining of “ideal” properties like functional groups, wettability, and surface charge.⁷¹ Methyl groups (–CH₃), for example, bind fibrinogen and IgG with high affinity, increasing phagocyte motility, leukocyte adherence, and pro-inflammation. Hydroxyl groups (–OH) influence osteoblast differentiation and promote fibronectin unfolding at the biomaterial surface. Amine groups (–NH₂) interact more with fibronectin and albumin, influencing osteoblast differentiation.⁷² Carboxyl groups (–COOH) promote albumin and fibronectin adsorption while decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines production. Fibrogenic and angiogenic factors can both be induced by carboxyl groups. By altering the

surface of polyethylene terephthalate by photograph copolymerization, the influence of surface chemistry on immune cell activities and cytokine expression was examined.⁷³

5.1.2. Surface chemistry's influence on macrophage polarity. Other studies have explored the impact of surface chemistry on macrophage polarity. For example, Rostam *et al.* demonstrated that changing the surface chemistry of a biomaterial could impact macrophage polarity. When monocytes were cultured on a hydrophilic O₂-PS40 (O₂ plasma-etched polystyrene) surface, they differentiated towards an M1-like phenotype, as revealed by enhanced production of pro-inflammatory transcription factors like STAT1 and IRF5. Whereas cells cultivated on a hydrophobic polystyrene surface differentiated into an M2 phenotype with high MR receptor expression and enhanced production of anti-inflammatory cytokines IL-10 and CCL18.⁷⁴

5.1.3. The influence of surface chemistry on the FBR. Researchers have also investigated the effect of these functional group's density and distribution on the FBR. Nair *et al.*, for example, found that the species and density of surface chemical groups affected the degree of FBR. They investigated the effect of foreign body reaction in a mouse subcutaneous implantation paradigm employing propylene particles infused with OH and COOH groups. They discovered that OH-immobilized surfaces had the most robust response, while surfaces with COOH groups had the weakest response. However, the density of both groups does not affect the degree of FBR.⁷⁵ Shen *et al.* investigated the influence of protein-immobilized biomaterial surfaces on FBGC formation, TNF- α , and monocyte activity. TCPS (tissue culture polystyrene surface), PS (untreated polystyrene), and primaria were immobilized with albumin, fibrinogen, fibronectin, and IgG (immunoglobulin). Implant surfaces immobilized with IgG demonstrated higher FBGC formation, TNF α release, and



procoagulant activity of monocytes. At the same time, surfaces immobilized by fibrinogen and fibronectin had lower FBGC formation than untreated surfaces. Monocyte activity was highest on the Primaria-coated surface.⁷⁶ Hsieh *et al.* demonstrated that FBR could be minimized by layer-by-layer type I COL/HA (collagen/hyaluronic acid) deposition on a PDMS (polydimethylsiloxane) substrate. When these surfaces were implanted in rats, fibrotic encapsulation decreased by 29–57% compared to untreated PDMS surfaces, indicating lower FBR.⁷⁷

Surface chemistry has demonstrated increased or reduced cell adhesion based on their wettability.⁷⁸ Hydrophilic surfaces have a higher attraction for cells; they can cause more inflammation and the creation of a giant fibrous capsule around implants. However, according to some research, hydrophobic surfaces promote the formation of fibrous capsules and the recruitment of inflammatory cells.⁷⁹ The impact of different surface chemistry on cellular attachment and the formation of fibrous capsules around implants has been inconsistent in both *in vivo* and *in vitro* studies. This demonstrates the importance of gaining a deeper understanding of the effects of surface chemistry on biological responses to construct successful implanted device design and development.

5.2. Surface nanopatterns

It is critical to modify surface features of the implanted biomaterial with the ability to minimize macrophage fusion, which

alleviates/reduces FBR.⁹ Nanotopography modification is an excellent approach for developing smart multidirectional nano-interfaces that can predictably trigger and regulate the behavior of cells from many systems. Adding nanopatterned interfaces to bone biomaterials has been shown in studies to influence bone cell function and promote osteogenesis.⁸⁰ To that purpose, nanopatterns such as nanotubes, nanopits, nanofibers, nanodots, nanorods, nanogrooves, and nanopores have all been used. A schematic representation of these different types of nanopatterns has been presented in Fig. 5. When the biophysicochemical and mechanical parameters of these nanopatterns are appropriately managed, they can increase biomaterial performance. Furthermore, nanopatterns have demonstrated significant immunomodulatory effects and their direct impact on osteocytes.⁸¹ This illustrates the ability of nanopatterned alteration to influence immune cell response and lower FBR. Finally, altering the surface nanopattern (Fig. 5) of biomaterials could provide a potential option for lowering FBR and increasing the efficacy of medical implants.

5.2.1. Nanotubes. Nanotubes have shown therapeutic promise in various biological domains, including angiogenesis, blood coagulation, and medication delivery.⁸² Carbon nanotubes have been employed to improve the tenacity and longevity of biopolymers as scaffolds and drug delivery vehicles.⁸³

Nanotubes have increased bone-forming cell adhesion, diffusion, and osteogenic differentiation in orthopedic and dental



Fig. 5 A schematic representation of different nanopatterns used for immune response modulation. The graphic depicts various nanopatterns and the corresponding fabrication techniques used to modify immune responses. Nanopatterns are nanostructures with distinct surface characteristics that interact with immune cells and influence their behavior and functions.



applications.^{4,84} For example, electrochemical anodization of titanium (Ti) resulted in the self-ordering of TiO₂ nanotube arrays with pore diameters ranging from 30 to 175 nm. TiO₂ nanotubes with 30 nm and 80 nm pore diameters improved bone marrow-derived mesenchymal stem cell adhesion and spreading.⁸⁵ Another study found that vertically architected TiO₂ nanotubes with dimensions ranging from 30 nm to 100 nm were made using pure titanium (Ti) foil and were shown to increase ER stress and osteogenic proliferation in cells.⁸⁶ The use of mechanotransduction to create silicon nanotubes (VA-SiNT) resulted in a hollow structure of SiNTs that demonstrated exceptional success in Cas9 ribonucleoprotein gene delivery.⁸⁷ Titania nanotubes were reported to limit immune cell growth and adhesion in blood lysate, resulting in lower levels of macrophage inflammatory protein (MIP)-1, monocyte chemotactic protein (MCP)-1, IL-6, and IL-8.⁸⁸ Furthermore, TiO₂ nanotube surfaces, particularly those with a diameter of 80 nm, were observed to promote macrophage adhesion and proliferation while decreasing the production of TNF-, MCP-1, and MIP-1 in macrophage cell lines, with no detectable expression of IL-1 and IL-6.⁸⁹ Thin-film carbon-nanotube architectures generate nanoroughness, which can stimulate neuroendocrine PC12 cell proliferation and adhesion. This framework physically strains the 5 nm thick cell membrane, causing significant lateral displacement of sub-plasmalemmal secretory vesicles.⁹⁰

Despite the research performed to understand the effect of nanotubes on orthopedic/dental applications, drug transport, and immune response modification. More research is required to understand the mechanisms underlying these effects and enhance nanotube-based material design. Furthermore, the potential toxicity of these substances must be thoroughly investigated to ensure their safe use in clinical settings. Developing new manufacturing techniques and integrating nanotubes with other modern technologies, such as gene editing and tissue engineering, may pave the way for the future application of nanotube-based materials in biomedicine.

5.2.2. Nanocolloids. Nanocolloids, specifically nanoparticles (NPs), have received much attention in the medical community for their therapeutic and diagnostic applications. Surface changes of nanocolloids, along with drug or contrast agent encapsulation, have enabled the development of novel carriers for medicines and imaging chemicals.⁹¹ Recent research has revealed that the surface characteristics of nanocolloids play an essential role in the regulation of protein interactions, innate immune responses, and foreign body responses. Moyano *et al.* investigated the surface modalities of nanocolloids and their impact on immunogenic responses following immune-mediated inflammatory reactions. In both *in vitro* and *in vivo* models, they discovered that the surface characteristics of nanocolloid particles could alter immune system reactivity. The findings revealed that hydrophobic zwitterionic nanoparticles elicited strong immunological responses, but hydrophilic zwitterionic nanoparticles induced minor immune responses. Interestingly, nanocolloids containing hydroxylated tetraethylene glycol (TEGOH) headgroups showed a significant

anti-inflammatory effect. This indicates that nanocolloid surface ligands may have immunomodulatory properties, opening the door to possible therapeutic uses in inflammatory illnesses.⁹² Several studies, in addition to Moyano *et al.*, have investigated the effect of nanocolloid-based nanotopography on protein interactions and immune responses. Using gold nanocolloid particles, researchers explored the regulation of chemokines from monocytes.⁹² The outer topographic coating of the nanocolloid surface with lipid-based materials can impact chemokine behavior, decreasing the generation of certain inflammatory factors.⁹³ Peptide-enhanced gold nanocolloids containing aromatic and hydrophobic groups, for example, were discovered to suppress the release of particular chemokines linked with inflammation.^{94,95}

These results show that the nanotopography of nanocolloids can influence protein interactions, innate immune responses, and foreign body responses. It is feasible to manage immunological reactions and inflammation by precisely tailoring the surface features of nanocolloids, such as their hydrophobicity, hydrophilicity, or ligand composition. This understanding opens up new prospects for creating nanocolloids with specific surface characteristics that can promote desired immune responses, reduce adverse reactions, and improve the biocompatibility of medical implants and devices. Further research in this area will help to build advanced nanocolloid-based therapeutic treatments and implantable biomedical devices.

5.2.3. Nanopits. Nanopits are well-defined topographical architectures that simulate bone tissue engineering functionality (dental implant, joint replacement, and bone repair). Polystyrene nanopit surfaces with diameters ranging from 300 to 400 nm have been shown in studies to induce osteogenic differentiation of human adipose-derived stem cells (hADSCs).⁹⁶ Nanopits created employing electron-beam lithography on polymeric surfaces have also increased bone-specific gene expression in mesenchymal stem cells (MSCs).⁹⁷ Another study found that highly ordered nanopits failed to guide osteogenic differentiation of human MSCs; however, randomly arranged nanopits did, implying that nanotopographical cues can promote osteogenesis without pharmacological stimulation.⁹⁸ The size and form of nanotopographical elements are essential variables in determining stem cell destiny. Human MSCs were induced to differentiate into osteoblast-like cells by the outermost titanium oxide nanopit layers ranging from 70 to 100 nm, whereas narrower 30 nm nanopits promoted cell attachment without differentiation.⁹⁹ During bone remodeling and absorption, osteoclasts form 40 μm-diameter pits in the seal zone while breaking down older bone tissue, demonstrating that nanopit topographical characteristics are essential in determining osteogenesis. Changing the parameters of nanopit topographies (pit diameter and depth) drastically altered the behaviors of bone-forming cells, with osteogenic differentiation improved under appropriate nanopit topologies.¹⁰⁰ Cellular attachment and spreading are affected by the diameter, spacing, and symmetry of nanopits, with cellular adhesion and integrin expression rising when the dimension of the nanopit surface is between 10 and 20 nm (height and depth). The size of the pits is increased to 100 nm, which inhibits cellular adhesion. Nanopits may have immunomodulatory effects due to



their capability to influence immune cell adhesion.¹⁰¹ Circular nanopits of 220 nm diameter etched on polycaprolactone (PCL) plates with pre-fabricated nickel chips stimulated osteoprogenitor cells, improving osteogenesis.¹⁰² These findings imply that nanopit topographic structures could have orthopedic and dental uses.

5.2.4. Nanofibers. Nanofibers are scaffolds or mats with a distinct and enhanced architectural structure that have the potential to be used in a variety of biotechnology and medicine applications. It has several applications, but it has acquired popularity in healthcare due to the benefits of its formulation in wound healing, drug administration, skin regeneration, and tissue engineering procedures. Nanofibers have a larger surface area, porosity, strength, elasticity, excellent extensibility, and interconnectivity, all contributing to the wound-healing cascade.¹⁰³ Nanofibers have long been regarded as important scaffolds due to their similar structure to the natural extracellular matrix, which aids in gas exchange and provides an optimal environment for improved cell adhesion, proliferation, and differentiation.^{104,105} Template synthesis, drawing process, self-assembly, electrospinning, and phase separation are examples of nanofiber production methods.¹⁰⁶ Electrospun nanofibers, for example, are great platforms for wound dressings because they provide a moist environment and may be impregnated with various biological components to aid wound healing applications.¹⁰⁷ The porosity design of the electrospun structure encourages cell migration and proliferation in the wound, permitting ventilation and moisture absorption. The wound bed penetration of electrospun nanofibrous scaffolds accelerates the inflammatory phase of the wound healing cascade. They also help with angiogenic effects, moisture retention, exudate absorption, endothelial cell migration, redox signaling, and cytoskeleton reorganization.¹⁰³ Hence, nanofibers aid wound healing by enhancing tissue repair, epithelialization regeneration, and vascularization potential.

The biocompatibility of implantable immunoisolation membranes is crucial for preventing fibrotic deposition, which can impair the function of encapsulated cells. Nanoscale fiber structure may aid macrophage cell regulation toward anti-inflammatory phenotypes *in vitro*. Wang *et al.* created electrospun membranes with various topographies of thermoplastic polyurethane (TPU) and micro- or nanofibers (PU-micro). Electrospun nanofibers modestly increased FBR compared to microfibrinous membranes, with little activation of macrophage cells.¹⁰⁸ To manage the macrophage phenotypic shift and minimize FBR, Song *et al.* inserted a short peptide termed mechano-growth factor (MGF) into an electrospun polycaprolactone (PCL) fibrous scaffold. MGF stimulates histone acetylation and increases STAT6 expression, resulting in an anti-inflammatory phenotype. A scaffold with MGF activity can inhibit FBR at the subcutaneous tissue level and prevent tissue adhesion.¹⁰⁹ Suyeoshi *et al.* investigated the efficacy of nano-PGA on the kinetics of cells migrating after transplantation. The immunohistochemistry examination revealed that using nano-PGA caused an early inflammatory reaction. Nano-PGA sheets demonstrated enhanced tissue compatibility compared to regular PGA by triggering early polarization to the M2

phenotype, leading to angiogenesis and tissue repair.¹¹⁰ Veleirinho *et al.* developed PET-based electrospun non-absorbable mats for the correction of abdominal malformations in the absence of intestinal adhesion. The electrospun meshes were flexible and had excellent suture retention.¹¹¹ However, mice-fed nanofibrous materials demonstrated a strong FBR, with PET and PET/chitosan groups exhibiting numerous FBGC, including nanofiber pieces. PET microfibers, on the other hand, have no discernible FBR.¹¹¹ According to Cao *et al.*, the topography of polycaprolactone (PCL) based on random and aligned electrospun nanofibers influences the FBR. Primary monocytes were collected and cultured *in vitro* on PCL nanofibers and PCL film. It was concluded that adhesion on the aligned scaffold was lower than on the random scaffold. The study suggests that aligned electrospun nanofibers may be a suitable scaffold for tissue engineering as they reduce host reactivity, increase tissue-scaffold integration, and induce a thinner fibrous capsule.¹¹²

Laursen *et al.*'s work on pelvic organ prolapse (POP) treatment is an example of a study that uses nanofibers in a medical application. To model abdominal wall healing in aged female rats, the researchers implanted electrospun polycaprolactone (PCL) meshes covered with connective tissue growth factor (CTGF)/PEG-fibrinogen (PF) and rat mesenchymal stem cells. In an abdominal repair model in aged rats, CTGF/PF-coated electrospun PCL meshes containing stem cells displayed appropriate support, biocompatibility, and no mesh-related issues.¹¹³ In another study, Mukherjee *et al.* created a biodegradable poly L-lactic acid-co-poly-caprolactone nanofibrous mesh (P nanomesh) for POP repair bioengineered with endometrial mesenchymal stem/stromal cells (eMSC). *In vivo*, these bioengineered meshes displayed excellent tissue integration and immunomodulatory effects.¹¹⁴ Synthetic scaffolds are necessary for regenerative medicine applications. However, foreign body reactions might block regeneration and lead to implant failure. Vacanti *et al.* used the anti-inflammatory medication dexamethasone to create a tissue engineering scaffold. Poly(L-lactic acid) (PLLA) and poly(ϵ -caprolactone) (PCL) electrospun fibers were generated in the presence and absence of the steroid. Dexamethasone-containing PLLA fibers generated a less severe inflammatory response, aided tissue regeneration, and allowed human mesenchymal stem cells to attach to and grow on them *in vitro*.¹¹⁵

Liu *et al.* created hybrid scaffolds by co-electrospinning PCL microfibers and human placental extracellular matrix (ECM) nanofibers with heparin and IL-4. *In vitro* and *in vivo*, the hybrid scaffold initially stimulated migration, NO generation, endothelial cells (ECs) tube formation, migration and maturation of vascular smooth muscle cells (VSMCs), and ECM deposition. Synthetic polymer and dECM materials' synergistic benefits revealed the new potential for producing small-diameter vascular grafts (SDVGs) and immune-regulated materials for tissue regeneration applications.¹¹⁶ Schoenenberger *et al.* investigated how external mechanical stresses and inherent topological signals from electrospun biomaterials interact to govern macrophage activation and macrophage-tendon fibroblast cross-talk. In both mechanically loaded and unloaded conditions, aligned



or randomly oriented polycaprolactone nanofiber substrates were examined *in vitro* and *in vivo*. The findings revealed that macrophages might be essential mechanosensory cells in tendon regeneration. They hypothesized that biomaterial designs targeting the recruited cells biomechanical niche could influence the biological response.¹¹⁷ Zhu *et al.* developed a bi-layered vascular graft for rejuvenation using a circumferentially aligned microfiber for the internal layer and random nanofibers for the external layer, which enhances mechanical qualities and prevents bleeding after implantation. The vascular graft with a small diameter induced the regrowth of circumferentially aligned VSMCs, mimicking the configuration of native blood vessels.¹¹⁸

Xia *et al.* created a core-shell nanofibrous membrane polycaprolactone-curcumin/gelatin-tetracycline hydrochloride (PCL-Cur/GEL-TH) with antibacterial, anti-inflammatory and antioxidant properties for wound healing applications.¹¹⁹ In another study, the electrospinning of alginate/collagen nanofibers containing GUMS16-producing exopolysaccharide has increased cell viability and proliferation.¹²⁰ Ye *et al.* created a prodrug by polymerizing an indomethacin-containing precursor and loading it onto electrospun poly(ϵ -caprolactone)/gelatin nanofibers. The inflammation-responsive nanofiber scaffold could inhibit cytokine secretion from the LPS-induced RAW264.7 cellular model.¹²¹

He *et al.* created a composite dressing replicating natural skin qualities to improve wound healing. This dressing is made up of an outside hydrophobic layer with micro-nano structures made of poly(ϵ -caprolactone)/polystyrene (PCL/PS) microspheres and an interior hydrophilic layer with curcumin-containing aligned poly(ϵ -caprolactone)/gelatin. The nanofiber alignment is essential in polarizing pro-inflammatory M1 macrophages into the healing M2 phenotype, which regulates cell proliferation, migration, and angiogenesis. Curcumin's anti-inflammatory properties encourage macrophage polarization. However, aligned nanofibers have a robust immunomodulatory capacity. Exudate buildup and dehydration are permitted by the porous matrix, lowering the risk of infection. This dressing could be helpful in the treatment of burn wounds.¹²²

Through trilayer nanofiber scaffolds, electrospun nanofiber scaffolds show considerable potential for managing chronic inflammation in tissue regeneration.¹²³ In contrast, multifunctional electrospun nanofiber dressings can channel surplus biofluid into improving wound healing.¹²⁴ Diabetic wound tissue regeneration necessitates using a wound dressing with a porous structure and antioxidant properties (SSD-PG-PVA/KGM).¹²⁵ Creating an adhesive patch of gelatin nanofibrous membranes based on hyaluronic acid and integrated with several light-emitting diode (LED) arrays has demonstrated promising results in photobiomodulation treatment for improving wound healing.¹²⁶

The use of nanofiber-based scaffolds has been shown to improve bone regeneration significantly. In particular, the coating of a 3D hydrogel with nanofibers has been shown to shift the macrophage phenotype towards the M2 type, which is anti-inflammatory and pro-healing. Electrospun nanofiber polyurethane membranes produced only minor macrophage responses and few foreign body reactions when tested on RAW

264.7 macrophages.¹²⁷ Immunological responses were detected on PLLA scaffolds with varying fiber sizes and alignments, with the fiber diameter determined to be a critical factor in releasing pro-inflammatory cytokines.¹²⁸ Nanofibers demonstrated less inflammation than microfibers and unmodified PLLA scaffolds. As a result, the diameter of the fibers, rather than their alignment, was found to be the most critical component in macrophage activation and pro-inflammatory cytokine production.¹²⁹ Incorporating an appropriate nanofiber structure could considerably increase the biocompatibility of biomaterials.

5.2.5. Nanodots. Nanodots have garnered significant attention due to their ultrasmall nanostructures, excellent biocompatibility, and photocatalytic properties, making them promising for inflammation alleviation and wound healing applications. For example, copper peroxide (CuO₂) nanodots have been found to induce angiogenesis and improve the healing rate of diabetic ulcer wounds. CuO₂ nanodots applied to wound surfaces effectively eradicated methicillin-resistant *Staphylococcus aureus* (MRSA) germs, decreased inflammation, and stimulated angiogenesis, resulting in rapid wound healing in *in vivo* investigations. Furthermore, these nanodots displayed little systemic toxicity when applied to wound sites, indicating their potential for treating chronic diabetic ulcers.¹³⁰ Other types of nanodots have also been investigated for wound healing. Molybdenum disulfide quantum dots (MoS₂ DQ) were created and tested for their capacity to inhibit microorganisms *via* photodynamic effects. When subjected to simulated sunshine, MoS₂ DQ produced more reactive oxygen species (ROS) than MoS₂ nanosheets. Light-activated MoS₂ DQ enhanced antibacterial activity *in vivo*, aiding wound healing while maintaining high biocompatibility.¹³¹ Furthermore, laser-activated ultrasmall copper sulfide nanodots (CuS NDs) have been produced and shown to be more effective in treating chronic wounds. These CuS nanodots enhanced fibroblast cell migration and endothelial cell angiogenesis and inhibited multidrug-resistant bacteria, suggesting they could heal wounds.¹³² Using etching and codeposition of surfactin and 1-dodecanethiol, Chen *et al.* created photoluminescent gold nanodots (SFT/DT-Au NDs). When SFT/DT-Au NDs were evaluated *in vivo* as a dressing bandage on MRSA-infected wounds of Wistar rats, they displayed rapid wound healing with enhanced collagen synthesis and epithelialization.¹³³

Organic nanodots of carbon and graphene have also shown potential in wound healing. These nanodots can promote adequate wound healing without scar formation by leveraging their unique features, such as creating free radicals and photo-thermal effects. Carbon nanomaterials and H₂O₂ graphene quantum dots (GQD) have been used as wound disinfection band-aids, displaying synergistic bacteria suppression and wound healing effects, and rapid wound closure.¹³⁴ Xiang *et al.* synthesized polydopamine (PDA) and folic acid (FA) functionalized carbon nanodot-decorated ZnO, which showed sustained bactericidal activity and enhanced fibroblast growth resulting in rapid healing and closure of exposed wound surfaces.¹³⁵ Furthermore, on zinc oxide surfaces, functionalized carbon nanodots decorated with polydopamine (PDA)



and folic acid (FA) demonstrated prolonged bactericidal activity, increased fibroblast proliferation, and faster wound healing. These developments emphasize the potential of nanodots in improving wound treatment tactics, opening up new avenues for dealing with microbe-infested wounds, and boosting efficient healing processes. Ag nanodots have demonstrated a wide range of bactericidal capabilities, and efforts have been made to use them in wound healing.¹³⁶ Although Ag nanoparticle-based wound-healing dressings such as Acticoat[®] have demonstrated success, more research is being conducted to reduce related toxicities and improve therapeutic efficacy. Continued efforts are being made to facilitate the translation of advanced formulations from the laboratory to clinical settings, to reduce potential toxicities and increase therapeutic efficacy in wound care. Recently, a unique technique utilizing Ag nanoparticles (21–70 nm) embedded within an organic cellulose nanocrystal matrix has been developed. These Ag nanodot-based ointments and strips have improved healing results in acute wounds, including quicker neovascularization, increased collagen accumulation, and rapid re-epithelialization. The positive results are due to the synergistic action of cellulose nanocrystals, which have a high retention capacity for wound exudate absorption, Ag nanodot's antibacterial activity absorption, and the nanodot's antibacterial activity. The nanodots stick to bacterial membranes successfully, possibly interacting with intracellular proteins.¹³⁷

Gold nanodots and gold (Au) nanostructures have emerged as intriguing candidates for wound treatment owing to their inherent biocompatibility, versatility, antioxidant, and optical qualities.¹³⁸ Self-assembling Au nanodots (3 nm) were coupled with antibacterial surfactin polypeptide, resulting in substantial antimicrobial action. The greater efficiency of these nanodots in engaging bacterial membranes and subsequent breakdown contributes to quicker healing and better epithelialization in MRSA-infected wounds.¹³³ Surfactin-functionalized Au nanodots loaded with egg-white hydrolysate and 2-mercapto-1-methylimidazole have exhibited significant bactericidal capacity and improved wound healing in previous studies.¹³⁹ Furthermore, photobiomodulation treatment using Au quantum dots (QDs) of 22 nm size has demonstrated encouraging outcomes in wound healing by lowering inflammation, promoting angiogenesis, and improving collagen synthesis.¹⁴⁰

Copper (Cu) nanodots provide an alternative therapeutic method for treating chronic wounds with infections. Cu ions have therapeutic actions such as accelerating the expression of growth-promoting genes and proteins, including angiogenic vascular endothelial growth factors (VEGFs), and neutralizing the effects of hypoxia-inducible factors.¹⁴¹ By turning collected photons into heat, Cu-functionalized nanodots also have a regulated photothermal impact on bacteria.¹⁴² Furthermore, nanodots have immunomodulatory capabilities, altering immune cell shape, adhesion, and proliferation. The effects of different nanodot array sizes on macrophage and foam cell adherence, cytoskeleton development, and pro-inflammatory gene expression have been studied. The adherence of macrophages and foam cells increased on nanodot arrays ranging from 50 nm to 100 nm, whereas it reduced on arrays ranging from 100–200 nm. Vinculin

and actin filament immunofluorescence demonstrated higher cell adhesion and cytoskeleton growth on surfaces with microscopic nanotopography.¹⁰¹ Furthermore, the formation of titania nanodot patterns on titanium surfaces has shown modulatory effects on mesenchymal stem cell osteogenic differentiation, implying prospective orthopedic applications for regulating bone-forming cell behavior on implant surfaces.¹⁴³

5.2.6. Nanopillars. Altunas *et al.* created a chitosan–gelatin nanopillar structure doped with epidermal growth factor (EGF) using a nanoporous anodic alumina scaffold. The integration of EGF in the nanopillars provided topological and biochemical cues to improve the healing mechanism. *In vitro* studies revealed that nanopillar systems, with or without EGF, consistently increased cellular adhesion, fibronectin levels, and epidermal growth factor receptor (EGFR) expression above plain films. The EGF-doped customized nanopillar scaffolds showed continuous promotion of collagen fiber synthesis, quicker wound healing rate, and enhanced melanin deposition in an *in vivo* excisional model.¹⁴⁴ In another study by Xu *et al.* they used the oxygen plasma etcher technique to synthesize a semi-ordered nanopillar platform using polytetrafluoroethylene (PTFE). The resulting nanopillar platform exhibited good radial and axial homogeneity and outstanding *in vitro* bactericidal and anti-inflammatory characteristics. Furthermore, the platform aided in the deposition of collagen fibers and the migration of macrophages.¹⁴⁵ Dai *et al.* created a vertical nanopillar array on silicon wafers using a metal-guided chemical etching method. *In vitro* wound healing studies with PANC-1 cells on the nanopillar platform revealed that the cells were efficiently recruited and firmly fixed on the nanopillar array compared to flat surfaces.¹⁴⁶ This improved cell adhesion and anchoring on the nanopillars has significant ramifications for various biological functions, including migration, proliferation, and polarization.

Nanopillar arrays have also given a new tool for researching the mechanical relationship between the cell membrane and the nucleus in living cells. Researchers could analyze subnuclear deformation in functioning cells by adding arrays of vertical nanopillars. The findings show that nuclear stiffness and the opposing impacts of actin and intermediate filaments are essential in nanopillar-induced atomic deformation.¹⁴⁷ Furthermore, OrmoComp nanopillars of various dimensions have been created to study cortical neuron axonal development and progression. Compared to low pillars (100 nm), high OrmoComp nanopillars (400 nm) demonstrated significantly greater neurite aggregation and growth. Detailed studies of growth cone dynamics during axonal differentiation indicated that nanopillars promote elongation and early axon development, resulting in longer axons than a flat surface. The nanopillar's sidewalls provide a larger surface area for growth cone coupling, creating paxillin-rich adhesions that promote fast and sustained neurite development.¹⁴⁸

The unusual properties of nanopillars, such as their large surface area and optical and electrical capabilities, have obtained much interest in recent years. For example, using soft lithography to create biocompatible polyurethane acrylate (PUA) nanopillars and their development with human adipose-derived stem cells (hASCs) has revealed insights into



cell–nanopillar interactions such as shape alterations and cytoplasmic projections.¹⁴⁹ Another method, which uses ultra-violet-assisted capillary force lithography (UV-CFL), has enabled the synthesis of nanopillar pattern arrays with varying densities, demonstrating that optimal nanotopographical density conditions promote bone mineralization, cell adhesion, and proliferation, potentially offering applications in bone tissue engineering.¹⁵⁰ Furthermore, nanoengineered silk-based nanopillar arrays have been developed to regulate stem cell morphology, transforming them into ellipsoidal forms resembling chondrocytes found in natural cartilage's superficial zone. These manufactured nanopillar arrays can induce chondrogenesis and imitate the rheological properties of synovial fluids by inserting kartogenin using an ion implantation approach, making them ideal biomimetic implants for the superficial zone of natural cartilage.¹⁵¹ Nanopillar topography has been used successfully in stem cell-based tissue engineering to stimulate mesenchymal stem cell development and regulate stem cell fate. This method allows for the development of massive 3D cell aggregates and the upregulation of the osteogenic cellular matrix.¹⁵² Nanopillars provide a flexible and promising platform for biomedical research and applications because of their unique features and capacity to interact with cells at the nanoscale. Further research and developments in nanopillar technology can potentially transform fields such as regenerative medicine, medication delivery, and tissue engineering.

5.2.7. Nanogrooves. Compared to other topographies, grooved and microtextured surfaces have been discovered to provide orientational and directional cues to guide the morphogenesis of bone-forming cells, a process known as “contact guidance.” Electrospinning of longitudinal nanogrooves on a poly-L-lactic acid (PLLA) microfiber scaffold is one method for producing these surface characteristics. It has been demonstrated that nanogrooves promote quicker cellular adhesion, enhanced cell migration, and accelerated wound healing.¹⁵³ The formation of vascularized tissue architectures for regenerative purposes continues to be difficult since most existing techniques rely on cell autonomy or unregulated cell placement, which frequently fails to overcome nutritional transportation restrictions. However, promoting revascularization with a flexible three-dimensional disc-shaped scaffold with layered nanogrooves has shown promise. Through mechanotransduction processes, these 3D nanogrooves provide topographical cues that directly regulate cellular responses. Importantly, these nanogrooves stimulate osteogenesis and mineralization independently while providing an ideal environment for the prevascular-like endothelial organization.¹⁵⁴ It has been demonstrated that including lithographically inspired hydroxyapatite (HA)-incorporated polycaprolactone (PCL) parallel nanogrooves and equine bone powder (EBPs) in dental pulp stem cells (DPSCs) synergistically enhances osteogenesis. Surprisingly, the nanogrooves promoted cell elongation, whereas EBPs controlled cell dispersion and aggregation. Understanding the interaction of DPSCs with the substrate and DPSCs with EBPs is critical for stimulating bone development. This method, which combines nanotopography with EBPs membrane modification, holds promise for guided bone regeneration (GBR) and

guided tissue regeneration (GTR) barriers used in orthodontics and maxillofacial surgery.¹⁵⁵ Photolithography and electron beam lithography (EBL) has been used to study the behavior of cellular focal adhesion on nanoscale surfaces with small holes and grooves. Nanogroove platforms have been shown to improve tissue architecture by allowing extracellular matrix (ECM) molecules to self-orient dynamically, influencing cell adhesion and placement. The properties of nanogrooves have a significant impact on protein adsorption and integrin binding. Furthermore, nanogroove surfaces influence the orientation of focal adhesion and fibrinogenesis, whereas cells respond to tissue rigidity regardless of cell-substrate or cell-ECM stresses.¹⁵⁶ In response to nanotopographical signals, a broad spectrum of cells elongate and horizontally align toward nanogrooves. Cell contacts with nanogrooves might decrease spreading or increase filopodia formation, altering cellular polarity. Narrower grooves promote cell polarization but not wider ones. Cell polarization improved on heavier and more minor grooves but not broader grooves.¹⁵⁷ The existence of vertical and flat ledges in nanogroove topographies has a direct influence on focal adhesion by interrupting and enhancing integrin binding. These topographies also influence focal adhesion orientation and the expression of adsorbed proteins. Following filopodia extension, proteins and actin filaments align parallel to the grooves. Nanogroove topographies can affect collagen matrix alignment, essential for bone matrix growth. Furthermore, nanogroove topographies can direct immune cell attachment and distribution, influencing the number and proliferation of connected macrophages.¹⁵⁸

In this review, we have discussed the use of diverse nanotopography, such as nanocolloids, nanotubes, nanogrooves, nanopores, nanopits, nanofibers, and nanopillars, in controlling inflammatory responses. These nanotopography have distinct surface properties that interact with immune cells and significantly impact their behavior and functional responses. Researchers have successfully altered critical inflammatory processes by utilizing the qualities of each nanotopography, such as surface area, roughness, aspect ratio, and spatial arrangement. These include regulation of cytokine secretion, modulation of immune cell adhesion, migration and polarization, and tissue regeneration encouragement. Furthermore, the fabrication procedures used to create these different types of nanotopography differ, providing flexibility and personalization in biomedical applications. Table 3 summarizes the information from the respective sections, summarizing the impacts of these diverse nanotopography on the inflammatory response, including their specific fabrication techniques.

6. Synergistic effect of surface features on modulating protein interaction, inflammation, and FBR

Surface features are rapidly being recognized for their synergistic impact on protein interactions and innate immune responses, which can influence the magnitude and nature of the FBR. Specific dimensions and geometries of nanostructured surfaces



Table 3 Nanotopography and inflammatory response. This table summarizes the impact of several types of nanotopography on inflammatory response regulation. It summarizes major data from each section, emphasizing the impact of each type of nanotopography on critical components of inflammation such as cytokine release, immune cell adhesion, migration, polarization, and tissue regeneration. The table also includes information on the fabrication procedures for constructing these types of nanotopography

Type of nanotopography	Fabrication technique	Feature size	Effect	Ref.
Nanotubes	Anodization	15–100 nm, 30–100 nm	Increased angiogenesis, macrophage proliferation and cell adhesion	82, 84 and 86
Nanocolloids	Microwave irradiation, chemical method	2–20 nm	Increased secretion of anti-inflammatory cytokines and cell adhesion	92–94
Nanopits	Electron beam lithography	300–400 nm, 70–100 nm	Increased cellular adhesion and differentiation	96, 99 and 101
Nanofiber	Electrospinning	50–100 nm, 100–300 nm	Stimulates angiogenesis, proliferation of fibroblasts and endothelial cells	103, 105 and 106
Nanodots	Hydrothermal	12 nm dots with 25 nm period and 20 nm lines with 40 nm period, 21–70 nm	Stimulates angiogenesis, increased fibroblast proliferation and migration	130, 132, 133 and 137
Nanopillars	Anodization, chemical etching	15–100 nm	Increased macrophage proliferation and migration	145 and 147
Nanogrooves	Photolithography and electron beam lithography	10–120 nm	Increased protein adsorption, increased macrophage proliferation, increased cellular adhesion and migration	153, 156 and 158

have been found to affect macrophage polarization, favoring the anti-inflammatory M2 phenotype and facilitating tissue remodeling. Surface chemistry modifications, such as adding cell-adhesive peptides, extracellular matrix proteins, or synthetic chemical groups, have also improved protein adsorption, immune cell adherence, and activation.^{33,159} However, only a handful of studies have shown the synergistic effect of nanotopography and chemistry to develop biomaterials that can actively control FBR and inflammation, resulting in improved wound healing.

For instance, plasma polymerization has been used to regulate fibronectin adsorption and functionalization, revealing functional protein domains interacting with human gingival epithelial cells and promoting epithelial barrier development.¹⁶⁰ Other research has used plasma polymerization and gold nanoparticles to create surface nanotopography and chemistry and investigate their synergistic effects on immune cell modulation *via* protein adsorption and functionalization. Dabare *et al.* investigated the synergistic effect of nanostructures and chemistry on albumin adsorption and functionalization. They discovered that as the surface area of the nanotopography increased, so did the percentage of immobilized albumin, and the protein went through structural changes and lost alpha-helical structures. THP-1 immune cells bind to exposed peptide sequences generated by albumin unfolding on the surface to engage with surface-adsorbed albumin. The immune response could be pro-inflammatory or anti-inflammatory, depending on the peptide sequence revealed.¹⁴ In a subsequent study, immune cell modulation *via* binding and functionalization of fibrinogen was interrogated using the same surface nanotopography and chemistry.⁶³ In addition, another study demonstrated that protein expression, such as expression of collagens, can be controlled to a greater extent using a combination of nanotopography and chemistry, which is beneficial in regulating the FBR.³⁵

Several other studies investigated the combined effect of nanotopography and surface chemistry on the inflammatory

response; different-sized gold nanoparticles (AuNPs) were used to introduce nanotopography, while plasma polymerization was used to add surface chemistry (carboxyl, methyl, amine, and functional groups).⁴ Surprisingly, regardless of the surface chemistry, all surfaces showed decreased expression of pro-inflammatory cytokines. Furthermore, adding amine-coated surfaces reduced pro-inflammatory cytokine release and activated the M2 phenotype in macrophages.¹⁶¹ Another study found that carboxyl functional groups and nanotopography synergize in increasing osteoclast activity. Furthermore, the researchers discovered that smaller nanotopography (16 nm) with an amine coating demonstrated superior osteogenicity.¹⁶² Notably, the impact of surface nanotopography and chemistry on macrophage plasticity has also been studied. Nanotopography was discovered to be dominant in regulating the pro-inflammatory route, while surface chemistry is dominant in influencing the anti-inflammatory pathway.⁶ Damanik *et al.* developed an *in vitro* FBR mimicking model by employing surface microstructure to increase the biomaterial's oxygen content and surface area. The investigation provided substantial insight into using the tunable surface chemistry, roughness, wettability, and topography and their effect on cell-proliferation, cellular morphology, cellular attachment, and release of pro-inflammatory (IL-1 β , IL-6) and anti-inflammatory cytokines (TGF- β 1, IL-10).¹⁶³ Tan *et al.* fabricated a vascular graft of electrospun polycaprolactone (PCL) scaffolds using PIII with surface modification encompassing cytokine interleukin-4 immobilization. Functionalized bioactive surfaces manifested overexpression of anti-inflammatory M2 genes resulting in a reduced foreign body response.¹⁶⁴ In another study, 3D hybrid particles with modified surface nanotopography and chemistry investigated inflammatory and FBR responses *in vivo*. Researchers reported that collagen expression and the adhering immune cells were regulated using a combination of surface nanotopography and chemistry.¹⁶⁵ Furthermore, the effect of surface



nanotopography and silver (Ag) loading on the biomaterial-associated FBR was examined by Liu *et al.*¹⁶⁶ Their results showed that the nanotopography lowered the FBR, and the Ag-loaded samples had an acceptable effect with a less severe reaction, demonstrating the promise of their technique for increasing biomaterial biocompatibility.

These examples demonstrate the ability of customized surface characteristics to influence protein interactions, innate immune responses, and the FBR. It is now possible to induce macrophage polarization towards desirable phenotypes, enhance inflammation resolution, and facilitate tissue repair by developing biomaterial surfaces with distinct nanotopographical features and personalized surface chemistry. Surface features can be precisely engineered to modify protein and immune cell binding, regulate macrophage plasticity, and alter the amount and nature of the foreign body response. These synergistic effects are depicted in a graphical representation, illustrating the intricate interplay between nanotopography and chemistry in shaping the immune response. Fig. 6 shows a graphic representation of these synergistic effects. These advancements enable precise cellular activity modulation, the controlled release of bioactive chemicals, and enhanced biomaterial integration, paving the path for sophisticated biomedical applications.

7. Clinical translation and commercialization

Closing the research-to-clinical implementation gap is critical for widely using nanotopography and surface chemistry-based biomaterials in many biological applications. Extensive preclinical and clinical research is required to demonstrate the safety, effectiveness, and long-term performance of these sophisticated biomaterials. Strong scientific proof is required for successfully commercializing and integrating these technologies into healthcare settings.

Several examples of commercialized nanotopography and surface chemistry-based biomaterials demonstrate their clinical translation.

•For instance, NanoMesh™ was the first hernia repair device on the market with surface nano-modification, made of monofilament polypropylene (PP) and surface treated with accelerated neutral atom beam (ANAB) technology. The use of nanoMesh™ is approved for treating abdominal wall hernias, including inguinal (direct and indirect). ("nanoMesh™") is a patented hernia repair solution created and marketed by nano-Mesh™ LLC. Dental implants with changed surfaces are one commercial example of nanotopography and surface chemistry-based products.¹⁶⁷




Fig. 6 Synergistic effect of nanotopography and chemistry on modulating protein adhesion, unfolding, and subsequent innate immune response. The figure depicts the impact of various surface nanotopography and surface chemistry on protein adsorption, cell surface contact, and subsequent immunological reactions. The protein adsorption and unfolding process alters cell surface contacts, influencing cellular responses and immunological consequences. The interaction of nanotopography and chemistry provides a distinct microenvironment that regulates the cellular function and, as a result, the immune response.



•Hylomate's CellSense technology is another successful example. They offer two products (Hylomate Pouch and sheet) that are made of micro-engineered biosynthesized cellulose (BC) membrane and are used as a protective covering for cardiac implantable electronic devices (CIEDs). The BC membrane exhibited practicality and safety by reducing fibrotic tissue growth and enhancing access to the device pocket, potentially simplifying CIED revision operations.¹⁶⁸

•Dental implant manufacturer Straumann offers SLACTIVE surfaces with nanotopographical features and functional coatings to improve osseointegration and long-term implant success rates.^{169–172}

•The nanoVIS Ti surface technology utilized for spinal implants is another successful example. Compared to other surfaces commonly used in orthopedics, their implants with the nanotubular surface increased and accelerated calcified extracellular matrix production on human osteoblasts and mesenchymal stem cells at 21 days *in vitro*.^{173,174}

Summary and future perspective

Surface engineering in medical implants holds enormous promise for the future. We should expect the creation of increasingly more sophisticated and personalized implant surfaces as researchers dive deeper into understanding the intricate connections between surface characteristics, proteins, immune cells, and tissues. Careful control over nanotopography, surface chemistry, and the integration of bioactive substances may be required to obtain desirable biological responses. Furthermore, advances in nanotechnology, biomaterials, and manufacturing techniques will allow for the large-scale production of implants with customized surface properties. These advancements have the potential to transform healthcare by improving implant biocompatibility, lowering problems, and improving patient outcomes. Furthermore, ongoing surface modification research will pave the way for developing innovative implants that can actively respond to their surroundings and promote tissue regeneration. We can expect significant developments that will impact the future of healthcare and enhance the lives of countless people as we continue to harness the promise of surface engineering in medical implants. Here are some possible future pathways:

•**Multifunctional surfaces:** By combining multiple functionalities into a single surface, such as nanotopography with surface chemistry modifications and responsive materials, surfaces can respond dynamically to their surroundings, promoting precise control over cellular behavior and tissue regeneration.

•**Personalized biomaterials:** As 3D printing and nanofabrication techniques progress, creating patient-specific biomaterials with personalized nanotopography and surface chemistry is becoming increasingly possible. Such tailored techniques can increase biocompatibility, improve tissue integration, and promote patient-specific treatment outcomes.

•**Bioactive coatings:** Further study into bioactive coatings that mirror the composition and functionality of the extracellular matrix will be beneficial. These coatings can enhance

biocompatibility and therapeutic results by promoting certain cellular responses, facilitating tissue regeneration, and modulating the immunological response.

In conclusion, the future of biomaterial implants lies in the synergy of additive manufacturing and nanofabrication. By integrating these technologies, researchers and manufacturers can produce increasingly sophisticated and individualized implant surfaces. This integration will allow for a better understanding of the complicated relationships between surface characteristics, proteins, immune cells, and tissues, ultimately leading to superior biological responses. Their future applications span many areas, including regenerative medicine, drug delivery systems, bioelectronic interfaces, implantable sensors and devices, customized prosthetics and implants, and smart implants. These applications can transform healthcare by providing tailored, functional, and responsive solutions that can potentially improve patient outcomes and quality of life.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

AB thanks MICINN (Spain) for Juan de la Cierva incorporation fellowship IJC-2019-042374-1 and Generalitat de Catalonia (Marie Curie Cofund) for the Beatriu de Pinós Fellowship 2021 BP 00105. All the schematics were created with [BioRender.com](https://www.biorender.com).

References

- 1 D. Williams, *Biomaterials*, 2011, **32**, 1–2.
- 2 A. Carnicer-Lombarte, S.-T. Chen, G. G. Malliaras and D. G. Barone, *Front. Bioeng. Biotechnol.*, 2021, **9**, 622524.
- 3 N. A. Hotaling, L. Tang, D. J. Irvine and J. E. Babensee, *Annu. Rev. Biomed. Eng.*, 2015, **17**, 317–349.
- 4 Z. Chen, A. Bachhuka, F. Wei, X. Wang, G. Liu, K. Vasilev and Y. Xiao, *Nanoscale*, 2017, **9**, 18129–18152.
- 5 S. N. Christo, K. R. Diener, A. Bachhuka, K. Vasilev and J. D. Hayball, *Biomed Res. Int.*, 2015, **2015**, 342304.
- 6 A. Bachhuka, R. Madathiparambil Visalakshan, C. S. Law, A. Santos, H. Ebendorff-Heidepriem, S. Karnati and K. Vasilev, *ACS Appl. Bio Mater.*, 2020, **3**, 1496–1505.
- 7 H. Xue, Z. Zhang, Z. Lin, J. Su, A. C. Panayi, Y. Xiong, L. Hu, Y. Hu, L. Chen, C. Yan, X. Xie, Y. Shi, W. Zhou, B. Mi and G. Liu, *Bioact. Mater.*, 2022, **18**, 552–568.
- 8 T. C. Yadav, P. Gupta, S. Saini, S. Mohiyuddin, V. Pruthi and R. Prasad, *ACS Omega*, 2022, **7**, 8350–8363.
- 9 K. Harawaza, B. Cousins, P. Roach and A. Fernandez, *Mater. Today Bio*, 2021, **12**, 100152.
- 10 J. Li, X. Jiang, H. Li, M. Gelinsky and Z. Gu, *Adv. Mater.*, 2021, **33**, 2004172.
- 11 Y. He, Y. Gao, Q. Ma, X. Zhang, Y. Zhang and W. Song, *J. Nanobiotechnol.*, 2022, **20**, 510.



- 12 O. Veisheh and A. J. Vegas, *Adv. Drug Delivery Rev.*, 2019, **144**, 148–161.
- 13 E. Marin, F. Boschetto and G. Pezzotti, *J. Biomed. Mater. Res., Part A*, 2020, **108**, 1617–1633.
- 14 P. R. L. Dabare, A. Bachhuka, E. Parkinson-Lawrence and K. Vasilev, *Mater. Today Adv.*, 2021, **12**, 100187.
- 15 C. R. Jenney and J. M. Anderson, *J. Biomed. Mater. Res.*, 2000, **49**, 435–447.
- 16 T. A. Horbett, *J. Biomed. Mater. Res., Part A*, 2018, **106**, 2777–2788.
- 17 D. J. Fabrizio-Homan and S. L. Cooper, *J. Biomater. Sci., Polym. Ed.*, 1992, **3**, 27–47.
- 18 E. Mariani, G. Lisignoli, R. M. Borzì and L. Pulsatelli, *Int. J. Mol. Sci.*, 2019, **20**.
- 19 N. Tamassia, F. Bianchetto-Aguilera, F. Arruda-Silva, E. Gardiman, S. Gasperini, F. Calzetti and M. A. Cassatella, *Eur. J. Clin. Invest.*, 2018, **48**, e12952.
- 20 R. Sridharan, A. R. Cameron, D. J. Kelly, C. J. Kearney and F. J. O'Brien, *Mater. Today*, 2015, **18**, 313–325.
- 21 L. Davenport Huyer, S. Pascual-Gil, Y. Wang, S. Mandla, B. Yee and M. Radisic, *Adv. Funct. Mater.*, 2020, **30**, 1909331.
- 22 R. Klopffleisch and F. Jung, *J. Biomed. Mater. Res., Part A*, 2017, **105**, 927–940.
- 23 J. M. Anderson, A. Rodriguez and D. T. Chang, *Semin. Immunol.*, 2008, **20**, 86–100.
- 24 J. M. Anderson, *Annu. Rev. Mater. Res.*, 2001, **31**, 81–110.
- 25 S. J. Busuttil, V. A. Ploplis, F. J. Castellino, L. Tang, J. W. Eaton and E. F. Plow, *J. Thromb. Haemostasis*, 2004, **2**, 1798–1805.
- 26 C. Rosales, *Front. Physiol.*, 2018, **9**, 113.
- 27 J. Kzhyshkowska, A. Gudima, V. Riabov, C. Dollinger, P. Lavelle and N. E. Vrana, *J. Leukocyte Biol.*, 2015, **98**, 953–962.
- 28 C. Chu, L. Liu, S. Rung, Y. Wang, Y. Ma, C. Hu, X. Zhao, Y. Man and Y. Qu, *J. Biomed. Mater. Res., Part A*, 2020, **108**, 127–135.
- 29 J. R. Nakkala, Z. Li, W. Ahmad, K. Wang and C. Gao, *Acta Biomater.*, 2021, **123**, 1–30.
- 30 E. W. Ozpinar, A. L. Frey, G. Cruse and D. O. Freytes, *Tissue Eng., Part B*, 2020, **27**, 590–603.
- 31 Y. Chen, W. Sun, H. Tang, Y. Li, C. Li, L. Wang, J. Chen, W. Lin, S. Li, Z. Fan, Y. Cheng and C. Chen, *Front. Bioeng. Biotechnol.*, 2022, **10**.
- 32 Z. Sheikh, P. J. Brooks, O. Barzilay, N. Fine and M. Glogauer, *Materials*, 2015, **8**, 5671–5701.
- 33 A. Bachhuka, J. Hayball, L. E. Smith and K. Vasilev, *ACS Appl. Mater. Interfaces*, 2015, **7**, 23767–23775.
- 34 M. Meyer, *Biomed. Eng. OnLine*, 2019, **18**, 24.
- 35 A. Bachhuka, J. D. Hayball, L. E. Smith and K. Vasilev, *ACS Appl. Mater. Interfaces*, 2017, **9**, 5874–5884.
- 36 K. E. Martin and A. J. García, *Acta Biomater.*, 2021, **133**, 4–16.
- 37 J. B. Parker, M. F. Griffin, A. F. Spielman, D. C. Wan and M. T. Longaker, *Adv. Text. Wound Care*, 2022, **12**, 85–96.
- 38 D. G. Barone, A. Carnicer-Lombarte, P. Tourlomis, R. S. Hamilton, M. Prater, A. L. Rutz, I. B. Dimov, G. G. Malliaras, S. P. Lacour, A. A. B. Robertson, K. Franze, J. W. Fawcett and C. E. Bryant, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**, e2115857119.
- 39 J. S. Desgrosellier and D. A. Cheresch, *Nat. Rev. Cancer*, 2010, **10**, 9–22.
- 40 V. K. Lishko, N. P. Podolnikova, V. P. Yakubenko, S. Yakovlev, L. Medved, S. P. Yadav and T. P. Ugarova, *J. Biol. Chem.*, 2004, **279**, 44897–44906.
- 41 T. D. Zaveri, J. S. Lewis, N. V. Dolgova, M. J. Clare-Salzler and B. G. Keselowsky, *Biomaterials*, 2014, **35**, 3504–3515.
- 42 Y. Liu and T. Segura, *Front. Bioeng. Biotechnol.*, 2020, **8**.
- 43 B.-H. Cha, S. R. Shin, J. Leijten, Y.-C. Li, S. Singh, J. C. Liu, N. Annabi, R. Abdi, M. R. Dokmeci, N. E. Vrana, A. M. Ghaemmaghami and A. Khademhosseini, *Adv. Healthcare Mater.*, 2017, **6**, 1700289.
- 44 Q. Zhao, N. Topham, J. M. Anderson, A. Hiltner, G. Lodoen and C. R. Payet, *J. Biomed. Mater. Res.*, 1991, **25**, 177–183.
- 45 M. Lamkanfi and V. M. Dixit, *Cell*, 2014, **157**, 1013–1022.
- 46 W.-J. Zhang, S.-J. Chen, S.-C. Zhou, S.-Z. Wu and H. Wang, *Front. Immunol.*, 2021, **12**.
- 47 J. M. Anderson, *ASAIO Trans*, 1988, **34**, 101–107.
- 48 S. Franz, S. Rammelt, D. Scharnweber and J. C. Simon, *Biomaterials*, 2011, **32**, 6692–6709.
- 49 S. Christo, A. Bachhuka, K. R. Diener, K. Vasilev and J. D. Hayball, *Sci. Rep.*, 2016, **6**, 26207.
- 50 J. L. Turley, H. B. T. Moran, C. P. McEntee, K. O'Grady, N. Muñoz-Wolf, L. Jin, F. Follmann, P. Andersen, M. Andersson and E. C. Lavelle, *Biomaterials*, 2021, **275**, 120961.
- 51 A. F. Malik, R. Hoque, X. Ouyang, A. Ghani, E. Hong, K. Khan, L. B. Moore, G. Ng, F. Munro, R. A. Flavell, Y. Shi, T. R. Kyriakides and W. Z. Mehal, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 20095–20100.
- 52 M. Court, M. Malier and A. Millet, *Biomaterials*, 2019, **208**, 98–109.
- 53 D. P. Vasconcelos, C. de Torre-Minguella, A. I. Gomez, A. P. Águas, M. A. Barbosa, P. Pelegrin and J. N. Barbosa, *Acta Biomater.*, 2019, **91**, 123–134.
- 54 A. C. Reissetter, L. V. Stebounova, J. Baltrusaitis, L. Powers, A. Gupta, V. H. Grassian and M. M. Monick, *J. Biol. Chem.*, 2011, **286**, 21844–21852.
- 55 O. Lunov, T. Syrovets, C. Loos, G. U. Nienhaus, V. Mailänder, K. Landfester, M. Rouis and T. Simmet, *ACS Nano*, 2011, **5**, 9648–9657.
- 56 D. M. Gómez, S. Urcuqui-Inchima and J. C. Hernandez, *Innate Immun.*, 2017, **23**, 697–708.
- 57 E. Abbasi-Oshaghi, F. Mirzaei and M. Pourjafar, *Int. J. Nanomed.*, 2019, **14**, 1919–1936.
- 58 F. Lebre, M. C. Pedroso de Lima, E. C. Lavelle and O. Borges, *Int. J. Pharm.*, 2018, **552**, 7–15.
- 59 M. S. Caicedo, L. Samelko, K. McAllister, J. J. Jacobs and N. J. Hallab, *J. Orthop. Res.*, 2013, **31**, 1633–1642.
- 60 F. Lebre, R. Sridharan, M. J. Sawkins, D. J. Kelly, F. J. O'Brien and E. C. Lavelle, *Sci. Rep.*, 2017, **7**, 2922.
- 61 M. Rahmati and M. Mozafari, *Mater. Today Commun.*, 2018, **17**, 527–540.



- 62 C. J. Wilson, R. E. Clegg, D. I. Leavesley and M. J. Pearcy, *Tissue Eng.*, 2005, **11**, 1–18.
- 63 R. M. Visalakshan, A. A. Cavallaro, M. N. MacGregor, E. P. Lawrence, K. Koynov, J. D. Hayball and K. Vasilev, *Adv. Funct. Mater.*, 2019, **29**, 1807453.
- 64 J. Rozga, T. Piątek and P. Małkowski, *Ann. Transplant.*, 2013, **18**, 205–217.
- 65 A. H. Morris and T. R. Kyriakides, *Matrix Biol.*, 2014, **37**, 183–191.
- 66 H. Amani, H. Arzaghi, M. Bayandori, A. S. Dezfouli, H. Pazoki-Toroudi, A. Shafiee and L. Moradi, *Adv. Mater. Interfaces*, 2019, **6**, 1900572.
- 67 M. Rafiei, J. T. Chung and Y. Chau, *Front. Drug Delivery*, 2023, **3**.
- 68 M. Rahmati, E. A. Silva, J. E. Reseland, C. A. Heyward and H. J. Haugen, *Chem. Soc. Rev.*, 2020, **49**, 5178–5224.
- 69 P. Thevenot, W. Hu and L. Tang, *Curr. Top. Med. Chem.*, 2008, **8**, 270–280.
- 70 J. T. Yates and C. T. Campbell, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 911–916.
- 71 E. Ruckenstein and Z. F. Li, *Adv. Colloid Interface Sci.*, 2005, **113**, 43–63.
- 72 J. N. Barbosa, P. Madureira, M. A. Barbosa and A. P. Águas, *J. Biomed. Mater. Res., Part A*, 2006, **76A**, 737–743.
- 73 K. M. Evans-Nguyen, L. R. Tolles, O. V. Gorkun, S. T. Lord and M. H. Schoenfish, *Biochemistry*, 2005, **44**, 15561–15568.
- 74 H. M. Rostam, S. Singh, F. Salazar, P. Magennis, A. Hook, T. Singh, N. E. Vrana, M. R. Alexander and A. M. Ghaemmaghami, *Immunobiology*, 2016, **221**, 1237–1246.
- 75 A. Nair, L. Zou, D. Bhattacharyya, R. B. Timmons and L. Tang, *Langmuir*, 2008, **24**, 2015–2024.
- 76 M. Shen, I. Garcia, R. V. Maier and T. A. Horbett, *J. Biomed. Mater. Res., Part A*, 2004, **70A**, 533–541.
- 77 C. Y. C. Hsieh, F.-W. Hu, W.-S. Chen and W.-B. Tsai, *ISRN Biomater.*, 2014, **2014**, 718432.
- 78 K. Jung, N. Corrigan, E. H. H. Wong and C. Boyer, *Adv. Mater.*, 2022, **34**, 2105063.
- 79 D. J. Menzies, B. Cowie, C. Fong, J. S. Forsythe, T. R. Gengenbach, K. M. McLean, L. Puskar, M. Textor, L. Thomsen, M. Tobin and B. W. Muir, *Langmuir*, 2010, **26**, 13987–13994.
- 80 J. M. Łopacińska, C. Grădinaru, R. Wierzbicki, C. Kølber, M. S. Schmidt, M. T. Madsen, M. Skolimowski, M. Dufva, H. Flyvbjerg and K. Mølhav, *Nanoscale*, 2012, **4**, 3739–3745.
- 81 D.-H. Kim, P. P. Provenzano, C. L. Smith and A. Levchenko, *J. Cell Biol.*, 2012, **197**, 351–360.
- 82 N. Saito, H. Haniu, Y. Usui, K. Aoki, K. Hara, S. Takanashi, M. Shimizu, N. Narita, M. Okamoto, S. Kobayashi, H. Nomura, H. Kato, N. Nishimura, S. Taruta and M. Endo, *Chem. Rev.*, 2014, **114**, 6040–6079.
- 83 J. Padmanabhan and T. R. Kyriakides, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2015, **7**, 355–370.
- 84 K. Gulati, *Surface Modification of Titanium Dental Implants*, Springer International Publishing, 2023.
- 85 M. Kingsak, P. Maturavongsadit, H. Jiang and Q. Wang, *Biomater. Transl. Med.*, 2022, **3**, 221–233.
- 86 S. Mengqi, S. Wen, Z. Boxin, L. Minni, Z. Yan, W. Qun and Z. Yumei, *Biomed. Mater.*, 2021, **16**, 15024.
- 87 Y. Chen, S. Aslanoglou, T. Murayama, G. Gervinskas, L. I. Fitzgerald, S. Sriram, J. Tian, A. P. R. Johnston, Y. Morikawa, K. Suu, R. Elnathan and N. H. Voelcker, *Adv. Mater.*, 2020, **32**, 2000036.
- 88 K. Gulati, S. Maher, D. M. Findlay and D. Losic, *Nanomedicine*, 2016, **11**, 1847–1864.
- 89 P. Roy, S. Berger and P. Schmuki, *Angew. Chem., Int. Ed.*, 2011, **50**, 2904–2939.
- 90 J. Zhang, D. Fu, M. B. Chan-Park, L.-J. Li and P. Chen, *Adv. Mater.*, 2009, **21**, 790–793.
- 91 A. K. Dey, A. Gonon, E.-I. Pécheur, M. Pezet, C. Villiers and P. N. Marche, *Cells*, 2021, **10**.
- 92 D. F. Moyano, Y. Liu, F. Ayaz, S. Hou, P. Puangpoy, B. Duncan, B. A. Osborne and V. M. Rotello, *Chem*, 2016, **1**, 320–327.
- 93 L. Foit and C. S. Thaxton, *Biomaterials*, 2016, **100**, 67–75.
- 94 H. Yang, S.-Y. Fung, S. Xu, D. P. Sutherland, T. R. Kollmann, M. Liu and S. E. Turvey, *ACS Nano*, 2015, **9**, 6774–6784.
- 95 W. Gao, Y. Wang, Y. Xiong, L. Sun, L. Wang, K. Wang, H. Y. Lu, A. Bao, S. E. Turvey, Q. Li and H. Yang, *Acta Biomater.*, 2019, **85**, 203–217.
- 96 C. Zhao, X. Song and X. Lu, *Int. J. Nanomed.*, 2020, **15**, 3281–3290.
- 97 M. J. Dalby, N. Gadegaard, R. Tare, A. Andar, M. O. Riehle, P. Herzyk, C. D. W. Wilkinson and R. O. C. Oreffo, *Nat. Mater.*, 2007, **6**, 997–1003.
- 98 T. Gong, J. Xie, J. Liao, T. Zhang, S. Lin and Y. Lin, *Bone Res.*, 2015, **3**, 15029.
- 99 D. Wähnert, J. Greiner, S. Brianza, C. Kaltschmidt, T. Vordemvenne and B. Kaltschmidt, *Biomedicines*, 2021, **9**, 746.
- 100 M. J. Davison, R. J. McMurray, C.-A. Smith, M. J. Dalby and R. M. D. Meek, *J. Tissue Eng.*, 2016, **7**, 2041731416652778.
- 101 M. Mohiuddin, H.-A. Pan, Y.-C. Hung and G. S. Huang, *Nanoscale Res. Lett.*, 2012, **7**, 394.
- 102 M. J. Davison, R. J. McMurray, M. J. Dalby and R. M. D. Meek, *Orthop. Proc.*, 2013, **95-B**, 54.
- 103 L. Sethuram and J. Thomas, *Biomed. Pharmacother.*, 2023, **157**, 113996.
- 104 V. S. Waghmare, P. R. Wadke, S. Dyawanapelly, A. Deshpande, R. Jain and P. Dandekar, *Bioact. Mater.*, 2018, **3**, 255–266.
- 105 T. Abdullah, K. Gauthaman, A. Mostafavi, A. Alshahrie, N. Salah, P. Morganti, A. Chianese, A. Tamayol and A. Memic, *Sci. Rep.*, 2022, **12**, 15051.
- 106 A. Eatemadi, H. Daraee, N. Zarghami, H. Melat Yar and A. Akbarzadeh, *Artif. Cells, Nanomed., Biotechnol.*, 2016, **44**, 111–121.
- 107 M. B. Stie, M. Corezzi, A. D. Juncos Bombin, F. Ajallouei, E. Attrill, S. Pagliara, J. Jacobsen, I. S. Chronakis, H. M. Nielsen and V. Foderà, *ACS Appl. Nano Mater.*, 2020, **3**, 1910–1921.



- 108 K. Wang, W.-D. Hou, X. Wang, C. Han, I. Vuletic, N. Su, W.-X. Zhang, Q.-S. Ren, L. Chen and Y. Luo, *Biomaterials*, 2016, **102**, 249–258.
- 109 Y. Song, L. Li, W. Zhao, Y. Qian, L. Dong, Y. Fang, L. Yang and Y. Fan, *Bioact. Mater.*, 2021, **6**, 2983–2998.
- 110 Y. Sueyoshi, A. Niwa, Y. Nishikawa and N. Isogai, *J. Biomed. Mater. Res., Part B*, 2023, **111**, 16–25.
- 111 B. Veleirinho, D. S. Coelho, P. F. Dias, M. Maraschin, R. Pinto, E. Cargnin-Ferreira, A. Peixoto, J. A. Souza, R. M. Ribeiro-do-Valle and J. A. Lopes-da-Silva, *PLoS One*, 2014, **9**, e95293.
- 112 H. Cao, K. Mchugh, S. Y. Chew and J. M. Anderson, *J. Biomed. Mater. Res., Part A*, 2010, **93A**, 1151–1159.
- 113 S. H. Laursen, S. G. Hansen, M. B. Taskin, M. Chen, L. Wogensen, J. V. Nygaard and S. M. Axelsen, *J. Biomed. Mater. Res., Part B*, 2023, **111**, 392–401.
- 114 S. Mukherjee, S. Darzi, K. Paul, F. L. Cousins, J. A. Werkmeister and C. E. Gargett, *Front. Pharmacol.*, 2020, **11**.
- 115 N. M. Vacanti, H. Cheng, P. S. Hill, J. D. T. Guerreiro, T. T. Dang, M. Ma, S. Watson, N. S. Hwang, R. Langer and D. G. Anderson, *Biomacromolecules*, 2012, **13**, 3031–3038.
- 116 S. Liu, L. Yao, Y. Wang, Y. Li, Y. Jia, Y. Yang, N. Li, Y. Hu, D. Kong, X. Dong, K. Wang and M. Zhu, *Bioact. Mater.*, 2023, **21**, 464–482.
- 117 A. D. Schoenenberger, H. Tempfer, C. Lehner, J. Egloff, M. Mauracher, A. Bird, J. Widmer, K. Maniura-Weber, S. F. Fucentese, A. Traweger, U. Silvan and J. G. Snedeker, *Biomaterials*, 2020, **249**, 120034.
- 118 M. Zhu, Z. Wang, J. Zhang, L. Wang, X. Yang, J. Chen, G. Fan, S. Ji, C. Xing, K. Wang, Q. Zhao, Y. Zhu, D. Kong and L. Wang, *Biomaterials*, 2015, **61**, 85–94.
- 119 D. Xia, Y. Liu, W. Cao, J. Gao, D. Wang, M. Lin, C. Liang, N. Li and R. Xu, *Int. J. Mol. Sci.*, 2022, **23**, 10983.
- 120 S. S. Ashraf, K. Parivar, N. Hayati Roodbari, S. Mashayekhan and N. Amini, *Int. J. Biol. Macromol.*, 2022, **196**, 194–203.
- 121 J. Ye, M. Gong, J. Song, S. Chen, Q. Meng, R. Shi, L. Zhang and J. Xue, *Pharmaceutics*, 2022, **14**, 1273.
- 122 C. He, B. Yu, Y. Lv, Y. Huang, J. Guo, L. Li, M. Chen, Y. Zheng, M. Liu, S. Guo, X. Shi and J. Yang, *ACS Appl. Mater. Interfaces*, 2022, **14**, 32799–32812.
- 123 V. Kumar, A. Kumar, N. S. Chauhan, G. Yadav, M. Goswami and G. Packirisamy, *ACS Appl. Bio Mater.*, 2022, **5**, 2726–2740.
- 124 X. Zhang, R. Lv, L. Chen, R. Sun, Y. Zhang, R. Sheng, T. Du, Y. Li and Y. Qi, *ACS Appl. Mater. Interfaces*, 2022, **14**, 12984–13000.
- 125 M. Yu, P. Tang, Y. Tang, C. Wei, Z. Wang and H. Zhang, *ACS Appl. Bio Mater.*, 2022, **5**, 2894–2901.
- 126 S. Y. Lee, S. Jeon, Y. W. Kwon, M. Kwon, M. S. Kang, K.-Y. Seong, T.-E. Park, S. Y. Yang, D.-W. Han, S. W. Hong and K. S. Kim, *Sci. Adv.*, 2023, **8**, eabn1646.
- 127 M. K. Haidar and H. Eroglu, *Curr. Top. Med. Chem.*, 2017, **17**, 1564–1579.
- 128 Y. Jia, W. Yang, K. Zhang, S. Qiu, J. Xu, C. Wang and Y. Chai, *Acta Biomater.*, 2019, **83**, 291–301.
- 129 J. Xie, M. R. MacEwan, A. G. Schwartz and Y. Xia, *Nanoscale*, 2010, **2**, 35–44.
- 130 R. Zhang, G. Jiang, Q. Gao, X. Wang, Y. Wang, X. Xu, W. Yan and H. Shen, *Nanoscale*, 2021, **13**, 15937–15951.
- 131 X. Tian, Y. Sun, S. Fan, M. D. Boudreau, C. Chen, C. Ge and J.-J. Yin, *ACS Appl. Mater. Interfaces*, 2019, **11**, 4858–4866.
- 132 Y. Qiao, Y. Ping, H. Zhang, B. Zhou, F. Liu, Y. Yu, T. Xie, W. Li, D. Zhong, Y. Zhang, K. Yao, H. A. Santos and M. Zhou, *ACS Appl. Mater. Interfaces*, 2019, **11**, 3809–3822.
- 133 W. Chen, H. Chang, J. Lu, Y. Huang, S. G. Harroun, Y. Tseng, Y. Li, C. Huang and H. Chang, *Adv. Funct. Mater.*, 2015, **25**, 7189–7199.
- 134 H. Sun, N. Gao, K. Dong, J. Ren and X. Qu, *ACS Nano*, 2014, **8**, 6202–6210.
- 135 Y. Xiang, C. Mao, X. Liu, Z. Cui, D. Jing, X. Yang, Y. Liang, Z. Li, S. Zhu, Y. Zheng, K. W. K. Yeung, D. Zheng, X. Wang and S. Wu, *Small*, 2019, **15**, 1900322.
- 136 M. Konop, T. Damps, A. Misicka and L. Rudnicka, *J. Nanomater.*, 2016, **2016**, 47.
- 137 R. Singla, S. Soni, V. Patial, P. M. Kulurkar, A. Kumari, Y. S. Padwad and S. K. Yadav, *Sci. Rep.*, 2017, **7**, 10457.
- 138 Y.-C. Yeh, B. Creran and V. M. Rotello, *Nanoscale*, 2012, **4**, 1871–1880.
- 139 B. Lu, F. Lu, L. Ran, K. Yu, Y. Xiao, Z. Li, F. Dai, D. Wu and G. Lan, *Int. J. Biol. Macromol.*, 2018, **119**, 505–516.
- 140 P. Lau, N. Bidin, S. Islam, W. N. B. W. M. Shukri, N. Zakaria, N. Musa and G. Krishnan, *Lasers Surg. Med.*, 2017, **49**, 380–386.
- 141 G. Borkow, J. Gabbay, R. Dardik, A. I. Eidelman, Y. Lavie, Y. Grunfeld, S. Ikher, M. Huszar, R. C. Zatcoff and M. Marikovsky, *Wound Repair Regen.*, 2010, **18**, 266–275.
- 142 X. Dai, Y. Zhao, Y. Yu, X. Chen, X. Wei, X. Zhang and C. Li, *ACS Appl. Mater. Interfaces*, 2017, **9**, 30470–30479.
- 143 Y. Hong, M. Yu, J. Lin, K. Cheng, W. Weng and H. Wang, *Colloids Surf., B*, 2014, **123**, 68–74.
- 144 S. Altuntas, H. K. Dhaliwal, A. E. Radwan, M. Amiji and F. Buyukserin, *Biomater. Sci.*, 2023, **11**, 181–194.
- 145 J. Xu, H. Moon, J. Xu, J. Lim, T. Fischer, H. A. McNally, H. O. Sintim and H. Lee, *ACS Appl. Mater. Interfaces*, 2020, **12**, 26893–26904.
- 146 J. Dai, Y. Lu, X.-Y. He, C. Zhong, B.-L. Lin, S. Ling, J. Gong and Y. Yao, *Appl. Mater. Today*, 2020, **20**, 100753.
- 147 L. Hanson, W. Zhao, H.-Y. Lou, Z. C. Lin, S. W. Lee, P. Chowdary, Y. Cui and B. Cui, *Nat. Nanotechnol.*, 2015, **10**, 554–562.
- 148 F. Milos, A. Belu, D. Mayer, V. Maybeck and A. Offenhäusser, *Adv. Biol.*, 2021, **5**, 2000248.
- 149 J. Kang, E.-H. Kang, Y.-S. Yun, S. Ji, I.-S. Yun and J.-S. Yeo, *Appl. Microsc.*, 2020, **50**, 26.
- 150 J. Kim, W.-G. Bae, K.-T. Lim, K.-J. Jang, S. Oh, K.-J. Jang, N. Li Jeon, K.-Y. Suh and J. Hoon Chung, *Mater. Lett.*, 2014, **130**, 227–231.
- 151 D. Dehghan-Baniani, B. Mehrjou, P. K. Chu and H. Wu, *Adv. Healthcare Mater.*, 2021, **10**, 2001018.
- 152 K. S. Brammer, C. Choi, C. J. Frandsen, S. Oh and S. Jin, *Acta Biomater.*, 2011, **7**, 683–690.



- 153 L. Zhan, L. Wang, J. Deng, Y. Zheng, Q. Ke, X. Yang, X. Zhang, W. Jia and C. Huang, *Nano Res.*, 2023, **16**, 1614–1625.
- 154 I. M. Bjørge, B. M. de Sousa, S. G. Patrício, A. S. Silva, L. P. Nogueira, L. F. Santos, S. I. Vieira, H. J. Haugen, C. R. Correia and J. F. Mano, *ACS Appl. Mater. Interfaces*, 2022, **14**, 19116–19128.
- 155 K.-J. Jang, S. Kim, S. Park, W. Kim, Y. Gwon, S. Park, K.-T. Lim, H. Seonwoo and J. Kim, *Appl. Sci.*, 2020, **10**.
- 156 H. N. Kim, A. Jiao, N. S. Hwang, M. S. Kim, D. H. Kang, D.-H. Kim and K.-Y. Suh, *Adv. Drug Delivery Rev.*, 2013, **65**, 536–558.
- 157 H. Rashidi, J. Yang and K. M. Shakesheff, *Biomater. Sci.*, 2014, **2**, 1318–1331.
- 158 E. T. den Braber, J. E. de Ruijter, L. A. Ginsel, A. F. von Recum and J. A. Jansen, *J. Biomed. Mater. Res.*, 1998, **40**, 291–300.
- 159 X. Liu, Q. Feng, A. Bachhuka and K. Vasilev, *ACS Appl. Mater. Interfaces*, 2014, **6**, 9733–9741.
- 160 S. Chen, Z. Huang, R. M. Visalakshan, H. Liu, A. Bachhuka, Y. Wu, P. R. L. Dabare, P. Luo, R. Liu, Z. Gong, Y. Xiao, K. Vasilev, Z. Chen and Z. Chen, *Biomater. Res.*, 2022, **26**, 88.
- 161 S. Chen, J. A. Jones, Y. Xu, H.-Y. Low, J. M. Anderson and K. W. Leong, *Biomaterials*, 2010, **31**, 3479–3491.
- 162 K. R. Kam, L. A. Walsh, S. M. Bock, J. D. Ollerenshaw, R. F. Ross and T. A. Desai, *Tissue Eng., Part A*, 2014, **20**, 130–138.
- 163 F. F. R. Damanik, T. C. Rothuizen, C. van Blitterswijk, J. I. Rotmans and L. Moroni, *Sci. Rep.*, 2014, **4**, 6325.
- 164 R. P. Tan, A. H. P. Chan, S. Wei, M. Santos, B. S. L. Lee, E. C. Filipe, B. Akhavan, M. M. Bilek, M. K. C. Ng, Y. Xiao and S. G. Wise, *JACC*, 2019, **4**, 56–71.
- 165 A. Bachhuka, S. N. Christo, A. Cavallaro, K. R. Diener, A. Mierczynska, L. E. Smith, R. Marian, J. Manavis, J. D. Hayball and K. Vasilev, *J. Colloid Interface Sci.*, 2015, **457**, 9–17.
- 166 M. Liu, K. Wu, L. Zhao and Y. Zhang, *J. Biomed. Nanotechnol.*, 2017, **13**, 381–392.
- 167 K. Baylón, P. Rodríguez-Camarillo, A. Elías-Zúñiga, J. A. Díaz-Elizondo, R. Gilkerson and K. Lozano, *Membranes*, 2017, **7**.
- 168 F. Robotti, I. Sterner, S. Bottan, J. M. Monné Rodríguez, G. Pellegrini, T. Schmidt, V. Falk, D. Poulidakos, A. Ferrari and C. Starck, *Biomaterials*, 2020, **229**, 119583.
- 169 S. Heberer, S. Kilic, J. Hossamo, J.-D. Raguse and K. Nelson, *Clin. Oral. Implants Res.*, 2011, **22**, 546–551.
- 170 N. Khandelwal, T. W. Oates, A. Vargas, P. P. Alexander, J. D. Schoolfield and C. Alex McMahan, *Clin. Oral. Implants Res.*, 2013, **24**, 13–19.
- 171 D. Schwartz-Arad, A. Laviv and L. Levin, *J. Periodontol.*, 2007, **78**, 219–223.
- 172 B. S. Kopf, S. Ruch, S. Berner, N. D. Spencer and K. Maniura-Weber, *J. Biomed. Mater. Res., Part A*, 2015, **103**, 2661–2672.
- 173 R. D. Guyer, J.-J. Abitbol, D. D. Ohnmeiss and C. Yao, *Spine*, 2016, **41**, E1146–E1150.
- 174 N. Wang, H. Li, W. Lü, J. Li, J. Wang, Z. Zhang and Y. Liu, *Biomaterials*, 2011, **32**, 6900–6911.

